WO1997017969A1 - Dihydropyrimidines and uses thereof - Google Patents

Dihydropyrimidines and uses thereof Download PDF

Info

Publication number
WO1997017969A1
WO1997017969A1 PCT/US1996/018573 US9618573W WO9717969A1 WO 1997017969 A1 WO1997017969 A1 WO 1997017969A1 US 9618573 W US9618573 W US 9618573W WO 9717969 A1 WO9717969 A1 WO 9717969A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
branched
straight chained
amount
subject
Prior art date
Application number
PCT/US1996/018573
Other languages
French (fr)
Inventor
Dhanapalan Nagarathnam
Wai C. Wong
Shou Wu Miao
Michael A. Patane
Charles Gluchowski
Original Assignee
Synaptic Pharmaceutical Corporation
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1995/015025 external-priority patent/WO1996014846A1/en
Application filed by Synaptic Pharmaceutical Corporation, Merck & Co., Inc. filed Critical Synaptic Pharmaceutical Corporation
Priority to AU10558/97A priority Critical patent/AU714287B2/en
Priority to JP9519157A priority patent/JP2000500470A/en
Priority to US09/068,782 priority patent/US6228861B1/en
Priority to EP96941406A priority patent/EP0866708A4/en
Publication of WO1997017969A1 publication Critical patent/WO1997017969A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • ⁇ 1A is the appellation recently approved by the IUPHAR Nomenclature Committee for the previously designated “ ⁇ 1C " cloned subtype as outlined in the 1995 Receptor and Ion Channel Nomenclature Supplement (Watson and Girdlestone, 1995).
  • the designation ⁇ 1A is used throughout this application and the supporting tables and figures to refer to this receptor subtype.
  • the receptor formerly designated ⁇ 1A was renamed ⁇ 1D .
  • the new nomenclature is used throughout this application. Stable cell lines expressing these receptors are described herein; however, these cell lines were deposited with the American Type Culture Collection (ATCC) under the old nomenclature (infra).
  • Benign Prostatic Hyperplasia also called Benign Prostatic Hypertrophy
  • Benign Prostatic Hypertrophy is a progressive condition which is characterized by a nodular enlargement of prostatic tissue resulting in obstruction of the urethra. This results in increased frequency of urination, nocturia, a poor urine stream and hesitancy or delay in starting the urine flow.
  • Chronic consequences of BPH can include hypertrophy of bladder smooth muscle, a decompensated bladder and an increased incidence of urinary tract infection.
  • the specific biochemical, histological and pharmacological properties of the prostate adenoma leading to the bladder outlet obstruction are not yet known. However, the development of BPH is considered to be an inescapable phenomenon for the aging male population.
  • Rev., 9, 407-533, 19 ⁇ 9 are specific neuroreceptor proteins located in the peripheral and central nervous systems on tissues and organs throughout the body. These receptors are important switches for controlling many physiological functions and, thus, represent important targets for drug development. In fact, many ⁇ -adrenergic drugs have been developed over the past 40 years. Examples include clonidine, phenoxybenzamine and prazosin (treatment of hypertension), naphazoline (nasal decongestant), and apraclonidine (treating glaucoma).
  • ⁇ -Adrenergic drugs can be broken down into two distinct classes: agonists (clonidine and naphazoline are agonists), which mimic the receptor activation properties of the endogenous neurotransmitter norepinephrine, and antagonists (phenoxybenzamine and prazosin are antagonists), which act to block the effects of norepinephrine. Many cf these drugs are effective but also produce unwanted side effects (for example, clonidine produces dry mouth and sedation in addition to its antihypertensive effects).
  • ⁇ -adrenergic receptors which exist throughout the central and peripheral nervous systems: ⁇ 1A (new nomenclature), ⁇ 1B , ⁇ 1D (new nomenclature), ⁇ 2A , ⁇ 2B and ⁇ 2C (Bylund, D.B., FASEB J., 6, 832 (1992)).
  • ⁇ 1A new nomenclature
  • ⁇ 1B new nomenclature
  • ⁇ 1D new nomenclature
  • ⁇ 2A , ⁇ 2B and ⁇ 2C Bolund, D.B., FASEB J., 6, 832 (1992)
  • current ⁇ -adrenergic drugs are not selective for any particular ⁇ -adrenergic receptor. Many of these drugs produce untoward side effects which may be attributed to their poor ⁇ -adrenergic receptor selectivity.
  • ⁇ 1A receptor is responsible for mediating the contraction of human prostate smooth muscle (Gluchowski, C. et. al., WO 94/10989, 1994; Forray, C. et. al., Mol. Pharmacol. 45, 703, 1994). This discovery indicates that the ⁇ 1A antagonists may be effective agents for the treatment of BPH with decreased side effects. Further studies have indicated that the ⁇ 1A receptor may also be present in other lower urinary tract tissues, such as urethral smooth muscle (Ford et al. Br. J. Pharmacol., 114, 24P, (1995)).
  • This invention is directed to dihydropyrimidine compounds which are selective antagonists for cloned human ⁇ 1A receptors.
  • This invention is also related to uses of these compounds for lowering intraocular pressure (Zhan, et. al. Ophthalmol. Vis. Sci., 34 Abst. #1133, 928, 1993), inhibiting cholesterol synthesis (D'Eletto and Javitt, J. Cardiovascular Pharmacol., 13 (Suppl. 2) S1-S4, 1989), benign prostatic hyperplasia, impotency (Milne and Wyllie, EP 0 459 666 A2, 1991), sympathetically mediated pain (Campbell, WO 92/14453, 1992), cardiac arrhythmia (Spiers, et. al., J. Cardiovascular Pharmacol., 16, 824-830, 1990) and for the treatment of any disease where antagonism of the ⁇ 1A receptor may be useful. Summary of the Invention
  • This invention is directed to dihydrcpyrimidine compounds which are selective antagonists for human a 1A receptors.
  • This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the ⁇ 1A receptor may be useful.
  • the invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
  • the present invention is directed to compounds having the structures:
  • each of Y 1 , Y 2 , Y 3 , Y, and Y 5 independently may be -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I; -NO 2 ; -N(R 3 ) 2 ; -N 3 ; -CN; -OR 3 ; -OCOR 3 ; -COR 3 ; -CON(R 3 ) 2 ; or -CO 2 R 3 ; or wherein two of Y 1 , Y 2 , Y 3 , Y 4 and Y s are present on adjacent carbon atoms
  • R 1 may be -H; -NO 2 ; -CN; straight chained cr branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 - C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R 3 ) 2 ; -OR 3 ; -(CH 2 ) p OR 3 ; -COR 3 ; -CO 2 R 3 ; or -CON(R 3 ) 2 , wherein any p independently is an integer from 1 to 7 inclusive; where R 2 may be -H; straight chained or branched C 1 -C 7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chaine
  • 2 may be C 2 -C 7 alkenyl or alkynyl
  • NR 3 NR 3 ; m is an integer from 0 to 3 inclusive; R 5 and R 6 each independently may be -H; -F,
  • C 1 -C 7 polyfluoroalkyl C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, or C 3 -C 7 cycloalkenyl, wherein the alkyl,
  • alkynyl, cycloalkyl or cycloalkenyl may be
  • heteroaryl aryl or heteroaryl wherein the
  • aryl or heteroaryl may be unsubstituted or
  • R 7 may be -H; straight chained or branched
  • aryl includes benzyl, benzoyl, naphthyl, or phenyl and heteroaryl includes pyridyl, thiophenyl, furanyl, pyrazinyl, pyrryl, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl, quinolyl, aminophenyl, benzimidazolyl or 2-keto-1-benzimidazolinyl.
  • the compounds of the present invention may be present as enantiomers, disteriomers, isomers or two or more of the compounds may be present to form a racemic mixture
  • the compounds of the present invention are preferably at least 80% pure, more preferably 90. pure, and most preferably 95% pure.
  • the invention further provides for the (+) enantiomer of any of the compounds described herein which is a cis isomer or trans isomer.
  • the invention also provides for the (-) enantiomer of any of the compounds described herein which is a cis isomer or trans isomer.
  • the compound is not (+)-6-(3,4-Difluorophenyl)-1-(N-[2-(4-cyano-4-phenyl-cyclohexylamino)ethyl] ⁇ carboxam ⁇ do-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride.
  • Preferred embodiments of the present invention include a compound selected from the group consisting of: and
  • R 4 is
  • R 4 is
  • the invention also provides for compounds having the following structure:
  • M is polyfluorophenyl and R 5 and R 6 are independently substituted or unsubstituted phenyl or pyridyl.
  • R 1 is -CO 2 CH 3 , -COCH 3 , or -CONH 2
  • R 2 is CH 2 OCH 3 , methyl or ethyl
  • R 6 is H, -CN, or CO 2 CH 3 .
  • the invention also provides for compounds having the following structure:
  • the invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the compounds described above and a pharmaceutically acceptable carrier.
  • a "therapeutically effective amount” is any amount of a compound which, when administered to a subject suffering from a disease against which the compounds are effective, causes reduction, remission, or regression of the disease
  • the therapeutically effective amount is an amount from about 0.01 mg per subject per day to about 500 mg per subject per day, preferably from about 0.1 mg per subject per day to about 60 mg per subject per day and most preferably from about 1 mg per subject per day to about 20 mg per subject per day.
  • the "pharmaceutically acceptable carrier” is any physiological carrier known to those of ordinary skill in the art useful in formulating pharmaceutical compositions.
  • the pharmaceutical carrier may be a liquid and the pharmaceutical composition would be in the form of a solution.
  • the pharmaceutically acceptable carrier is a solid and the composition is in the form of a powder or tablet.
  • the pharmaceutical carrier is a gel and the composition is in the form of a suppository or cream.
  • the invention provides a method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject any one of the compounds described herein effective to treat benign prostatic hyperplasia.
  • the invention further provides that the compound additionally does not cause a fall in blood pressure at dosages effective to alleviate benign prostatic hyperplasia.
  • the compound effects treatment of benign prostatic hyperplasia by relaxing lower urinary tract tissue and in particular where the lower urinary tract tissue is prostatic smooth muscle.
  • the invention further provides a method of treating a subject suffering from elevated intraocular pressure which comprises administering to the subject one of the compounds described herein effective to lower intraocular pressure.
  • the invention further provides a method of treating a subject suffering from a disorder associated with elevated blood cholesterol which comprises administering to the subject one of the compounds described herein effective to inhibit cholesterol synthesis.
  • the invention also provides a method of treating a disease which is susceptible to treatment by antagonism of the ⁇ 1A receptor which comprises administering to the subject one of the compounds described herein effective to treat the disease.
  • the invention further provides a method of treating a subject suffering from impotency which comprises administenng to the subject one of the compounds described herein effective to treat impotency.
  • the invention further provides a method of treating a subject suffering from sympathetically mediated pair, which comprises administering to the subject one of the compounds described herein effective to treat sympathetically mediated pain.
  • the invention provides a method of treating a subject suffering from cardiac arrhythmia which comprises administering to the subject one of the compounds described herein effective to treat cardiac arrhythmia.
  • This invention also provides a method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of any of the compounds described above in combination with a 5 alpha-reductase inhibitor effective to treat benign prostatic hyperplasia.
  • the 5-alpha reductase inhibitor is finasteride.
  • the dosage administered to the subject is about 0.01 mg per subject per day to 50 mg per subject per day of finasteride in combination with an ⁇ 1A antagonist.
  • a preferred dosage administered to the subject is about 0.2 mg per subject per day to 10 mg per subject per day of finasteride in combination with an ⁇ 1A antagonist.
  • a more preferred dosage administered to the subject is about 1 mg per subject per day to 7 mg per subject per day of finasteride in combination with an ⁇ 1A antagonist.
  • the most preferred dosage administered to the subject is about 5 mg per subject per day of finasteride in combination with an ⁇ 1A antagonist.
  • the invention also provides for a pharmaceutical composition comprising a therapeutically effective amount of a combination of any of the compounds described herein in combination with finasteride and a pharmaceutically acceptable carrier.
  • tne pnarmaceutical composition is a therapeutically effective amount of a combination comprising an amount from about 0.01 mg per subject per day to about 500 mg per subject per day of any one of the compounds ⁇ escnoed herein and an amount cf finasteride of about 5 mg per subject per day.
  • a more preferred embodiment of the pharmaceutical composition is a therapeutically effective amount of a combination comprising an amount from about 0.1 mg per subject per day to about 60 mg per subject per day of any one of the compounds described herein and an amount of the finasteride of about 5 mg per subject per day.
  • the most preferred embodiment of the pharmaceutical composition is a therapeutically effective amount of a combination comprising from about 1 mg per subject per day to about 20 mg per subject per day of any one of the compounds described herein and an amount of the finasteride of about 5 mg per subject per day.
  • the invention further provides a method of relaxing lower urinary tract tissue which comprises contacting the lower urinary tract tissue with an amount of one of the compounds described herein effective to relax lower urinary tract tissue.
  • the lower urinary tract tissue is prostatic smooth muscle.
  • the compound additionally does not cause a fall in blood pressure when it is effective to relax lower urinary tract tissue.
  • the invention provides a method of relaxing lower urinary tract tissue in a subject which comprises administering to the subject an amount of one of the compounds described herein effective to relax lower urinary tract tissue.
  • the compound does not cause a fall in blood pressure and the lower urinary tract tissue is prostatic smooth muscle.
  • the invention further provides for a method of innibiting contraction of prostatic tissue, which comprises administering to the subject an amount of any of the compounds described herein effective to inhibit contraction of prostatic tissue.
  • the prostatic tissue is prostatic smooth muscle and the compound additionally does not cause a fall in blood pressure.
  • the invention provides for the use of the compounds described herein for the preparation of a pharmaceutical composition for lowering intraocular pressure, inhibiting cholesterol synthesis, and the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the ⁇ 1A receptor may be useful.
  • the invention provides for the use of the compounds described herein for the preparation of a pharmaceutical composition for relaxing lower urinary tract tissue and in particular prostatic smooth muscle.
  • the invention further provides for the use of any of compounds described herein for the preparation of a pharmaceutical composition, where the compound additionally does not cause a fall in blood pressure at dosages effective to lower intraocular pressure, to inhibit cholesterol synthesis, and for the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the ⁇ 1A receptor may be useful.
  • the invention provides for the use of the compounds described herein in the preparation of a medicament for lowering intraocular pressure, inhibiting cholesterol synthesis, and for the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the ⁇ 1A receptor may be useful.
  • the invention provides for the use of the compounds described herein in the preparation of a medicament for relaxing lower urinary tract tissue and in particular prostatic smooth muscle.
  • the invention further provides for the use of any of compounds described herein in the preparation of a medicament, where the compound additionally does not cause a fall in blood pressure at dosages effective to lower intraocular pressure, to inhibit cholesterol syntnesis, and for the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the ⁇ 1A receptor may be useful.
  • the invention provides for a drug which is useful for lowering intraocular pressure, inhibiting cholesterol synthesis, and the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the ⁇ 1A receptor may be useful, the effective ingredient of the said drug being any of the compounds described herein.
  • the invention further provides the drug described herein additionally does not cause a fall in blood pressure at dosages effective to lower intraocular pressure, to inhibit cholesterol synthesis, and for the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the ⁇ 1A receptor may be useful.
  • the invention provides for a drug which is useful for relaxing lower urinary tract tissue and in particular prostatic smooth muscle, the effective ingredient of the drug being any of the compounds described herein.
  • the invention further provides the drug which is useful for relaxing lower urinary tract tissue additionally does not cause a fall in blood pressure at dosages effective to relax lower urinary tract tissue.
  • the invention also provides for the (-) and (+) enantiomers of all compounds of the subject application described herein. Included in this invention are pharmaceutically acceptable salts and complexes of all of the compounds described herein.
  • the salts include but are not limited to the following acids and bases.
  • the following inorganic aci ⁇ s, nydrocnloric acid, hydrofluoric acid, hydronromic acid, hydroiodic acid, sulfuric acid and boric acid The organic acids, acetic acid, trifluoroacetic acid, formic acid, oxalic acid, malonic acid, succiinc acid, fumaric acid tartaric acid, maleic acid, citric acid, methanesulfoinc acid, trifluoromethanesulfonic acid, benzoic acid, glycolic acid, lactic acid and mandelic acid.
  • the following inorganic bases ammonia, hydroxyethylamine and hydrazine.
  • the pharmaceutical carrier may be a liquid and the pharmaceutical composition would be in the form of a solution.
  • the pharmaceutically acceptable carrier is a solid and the composition is in the form of a powder or tablet.
  • the pharmaceutical carrier is a gel and the composition is in the form of a suppository or cream.
  • the compound may be formulated as a part of a pharmaceutically acceptable transdermal patch.
  • a solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary compression properties in suicacle proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient.
  • Suitable solid carriers include, for example, calcium pnosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions.
  • the active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmoregulators.
  • suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g.
  • cellulose derivatives preferably sodium carboxymethyl cellulose solution
  • alcohols including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil)
  • the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration.
  • the liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellent.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by for example, intramuscular, intrathecal, epidural, intraperitoneal or subcutaneous injection.
  • Sterile solutions can also be administered intravenously.
  • the compounds may be prepared as a sterile solid composition which may be dissolved or suspended at the time of administration using sterile water, saline, cr other appropriate sterile injectable medium.
  • Carriers are intended to include necessary and inert binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
  • the compound can be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents, for example, enough saline or glucose to make the solution isotonic, bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
  • a sterile solution or suspension containing other solutes or suspending agents, for example, enough saline or glucose to make the solution isotonic, bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
  • compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions.
  • forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
  • Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular compound in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of administration.
  • This invention further provides for metabolites of the compounds of the present invention.
  • the in vivo activities and mechanisms of action of numerous enzymes responsiole for the generation of metabolites of pharmaceutical compounds are well-known in the art.
  • ethers may be modified to alcohols
  • esters may be modified by esterases
  • amides may be modified by amidases and peptidases.
  • This invention further provides a prodrug of the compounds disclosed herein.
  • Knowledge of metabolic activities allows the design of prodrug compounds which, when administered to a
  • the cyclohexylamino nitrogen may be modified by various substituents, such as methyl, alkanoyl, aroyl, or an alkyl or aryl carbamate may be formed, which are expected to yield the compounds of the present invention when acted upon in vivo by endogenous enzymes. As stated above, such modifications are intended only as
  • Scheme 1 illustrates the general synthetic scheme for the preparation of the compounds of the present invention. Specific references to synthetic steps from Schemes 2-8 are included in the Examples below where appropriate. All NMRs were obtained using a 300 MHz GE QEPLUS NMR machine.
  • (+)-5-(Benzyloxycarbonyl)-1,6-dihydro-2-methoxy-4-ethyl-6-(2,4-difluorophenyl)pyrimidine (Scheme 3; Step C-3).
  • (+)-5(benzyloxycarbonyl) -4-ethyl-1,6-dihydro-1- ⁇ N-[2-phenyl)ethyl] ⁇ carboxamido- 2-methoxy-6-(2,4-difluorophenyl)pyrimidine 11.15 g, 20.41 mmol
  • toluene 250 mL
  • 1,8-diazabicyclo[5,4,0]-undec-7-ene (4.04 g, 26.53 mmol
  • (+)-6-(2,4-difluorophenyl)-1,6- dihydro-2-methoxy-5-benzyloxycarbonyl-4-ethyl-1-(4- nitrophenoxy)-carbonylpyrimidine 6.50 g, 11.81 mmol
  • dichloromethane 150 mL
  • 1N HCl in ether 50 mL
  • Solvent was evaporated at reduced pressure and the residue was dried to give 6.31 g (100%) of the product as a white powder .
  • amidopyrimidine-5-carboxylic acid as a white solid (276 g, 98%).
  • the product was used in the next step without further purification.
  • j ( + ) - cis - 5 - Carboxamido - 6 - ( 2 , 4 -difluorophenyl) -1- ⁇ N- [2- (4-cyano-4-phenylcyclohexylamino)ethyl] ⁇ carboxamido-4-ethyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride (Scheme 4; Step B-3).
  • the HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether. M.p. 225-228 °C; Anal. Calcd. for C 29 H 33 N 6 O 3 F 2 Cl.0.38H 2 O.0.19CH 2 Cl 2 :C, 57.47; H, 5.64; N, 13.75. Found: C, 57.80; H, 5.56; N, 13.37.
  • the first major product to elute was (+)-5-methoxycarbonyl-4-methoxmethyl-1,6-dihydro-1- ⁇ N-[2-phenyl)ethyl] ⁇ carboxamido-2-methoxy-6- (3,4-difluorophenyl)pyrimidine (1.74 g, 44.5%), as an oil.
  • (+)-5-Methoxycarbonyl-1,6-dihydro-2-methoxy-4- methoxymethyl-6-(3,4-difluorophenyl)pyrimidine Scheme
  • the racemic 5-methoxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine was resolved by chiral HPLC [Chiralcel OD 20 ⁇ 250 mm #369-703-30604; ⁇ 254 nm; hexanes/ethanol 95/5 and 0.01% diethylamine; 60 mg per injection; retention time of the desired enantiomer: 10.80 min., the first enantiomer peak to elute] to give (+)-5-methoxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine.
  • (+)-6-(3,4-difluorophenyl)-1,6-dihydro-2-methoxy-5-methoxycarbonyl-4-methoxymethyl-1- (4-nitrophenoxy)-carbonylpyrimidine (0.305 g, 0.60 mmol) in dichloromethane (15 mL)
  • 1N HCl in ether (6 mL) was added at room temperature and the mixture was stirred at room temperature for 12 hours.
  • Solvent was evaporated at reduced pressure and the residue was dried to give 0.295 g (100%) of the product as a white powder.
  • ethylamine (0.567 g, 2.42 mmol) in dichloromethane (30 mL) was stirred at room temperature for 12 hours. It was washed with ice-cold 0.5N NaOH (2 ⁇ 10 mL) and dried over sodium sulfate. Solvent was evaporated at reduced pressure and the residue was purified by flash chromatography on silica gel (dichloromethane:MeOH:2M ammonia in MeOH, 90:8:4) to give 0.905 g (90%) as a white powder.
  • the HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether. Anal. Calcd. for C 30 H 34 N 5 O 5 F 2 Cl:C, 58.30; H, 5.53; N, 11.06. Found: C, 57.99; H, 5.73; N, 11.20.
  • the HCl salts were prepared by treatment of a solution of the free base in ether with 1N HCl in ether.
  • Example 8 The cis isomer: M.P 145-146 °C; Anal. Calcd. for C 28 H 33 N 4 O 4 F 2 Cl 0.8H 2 O:C, 58.24; H, 6.04; N, 9.70. Found: C, 58.13; H, 5.83; N, 9.50.
  • Example 9 The trans isomer: M.P 156-157 °C; Anal. Calcd. for C 28 H 33 N 4 O 4 F 2 Cl 0.4CHCl 3 :C, 55.85; H, 5.51; N, 9.17. Found: C, 55.57; H, 5.76; N, 9.10.
  • (+)-6-(3,4-Difluorophenyl)-1,6-dihydro-2-oxo-5- methoxy-carbonyl-4-bromomethyl-1-[(4-nitrophenyloxy)carbonyl]pyrimidine Scheme 7; Step A).
  • (+)-6-(3,4- difluorophenyl) -1, 6-dihydro-2-methoxy-5- methoxycarbonyl-4-methyl-1-[(4-nitrophenyloxy) carbonyl]pyrimidine (1.5 mmol, 0.66 g) in 5 mL of chloroform was added a solution of bromine (1.5 mmol, 0.09 mL) in 3 mL of chloroform at 0°C and the solution was allowed to attain room temperature over 1.5 h. The solvent was removed in vacuo and the residue was again dissolved in CHCl 3 (20 mL) and washed with brine.
  • (+)-6-(3,4-Difluorophenyl)-1,6-dihydro-2-oxo-5-methoxycarbonyl-4-bromomethyl-1-[(4-nitrophenyloxy)carbcnyl]pyrimidine (1.5 mmol, 0.81 g) was heated in oil bath for 3 h (bath temperature 130°C.
  • (+)-5-benzyloxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine as a viscous oil (1.25 g, 86%).
  • (+)-6-(3,4-difluorophenyl)-1- ⁇ N-[2-(4-cyano-4-phenylcyclohex-1-ylamino)-ethyl] ⁇ carboxamido-5-benzyloxycarbonyl-4-methoxymethyl-2-oxo 1,2,3,6-tetrahydropyrimidine 120 mg
  • methanol/water 9/1, 10 mL
  • 10% palladium on charcoal (20 mg) was added and the mixture was hydrogenated at 125 psi for 4 h.
  • the t1c analysis of the reaction indicated the completion of the reaction.
  • an oral composition cf a compound of this invention 100 mg of one of tr.e compounds described herein is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.
  • Binding affinities were measured for selected compounds of the invention at six cloned human alpha-1 and alpha- 2 receptor subtypes, as well as at the L-type calcium channel. The protocols for these experiments are given below.
  • ⁇ 1D Human ⁇ drenergic Receptor The entire coding region of ⁇ 1D (1719 bp), including 150 base pairs of 5' untranslated sequence (5' UT) and 300 bp of 3' untranslated sequence (3' UT), was cloned into the BamHI and ClaI sites of the polylinker-modified eukaryotic expression vector pCEXV-3, called EXJ.HR.
  • the construct involved the ligation of partial overlapping human lymphocyte genomic and hippocampal cDNA clones: 5' sequence were contained on a 1.2 kb SmaI-XhoI genomic fragment (the vector-derived BamHI site was used for subcloning instead of the internal insert-derived Smal site) and 3' sequences were contained on an 1.3 kb XhoI-ClaI cDNA fragment (the Clal site was from the vector polylinker).
  • Stable cell lines were obtained by cotransfection with the plasmid ⁇ 1A/EXJ (expression vector containing the ⁇ 1A receptor gene (old nomenclature)) and the plasmid pGCcos3neo (plasmid containing the aminoglycoside transferase gene) into LM(tk-) cells using calcium phosphate technique.
  • the cells were grown, in a controlled environment (37°C., 5% CO 2 ), as monolayers in Dulbecco's modified Eagle's Medium (GIBCO, Grand Island, NY) containing 25mM glucose and supplemented with 10% bovine calf serum, 100 units/ml penicillin g, and 100 ⁇ g/ml streptomycin sulfate.
  • the cell line expressing the human ⁇ 1D receptor used herein was designated L- ⁇ 1A (old nomenclature) and was deposited with the American Type Culture Collection, 12301 Parklavm Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
  • the cell line expressing the human ⁇ 10 receptor was accorded ATCC Accession No.
  • ⁇ 1B Human Adrenergic Receptor The entire coding region of ⁇ 1B (1563 bp), including 200 base pairs and 5' untransiated sequence (5' UT) ana 600 bp cf 3' untranslated sequence (3' UT), was cloned into tne EcoRI site of pCEXV-3 eukaryotic expression vector The construct involved ligating the full-length containing EcoRI brainstem cDNA fragment from ⁇ ZapII into the expression vector. Stable cell lines were selected as described above.
  • the cell line used herein was designated L- ⁇ 1B and was deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20832, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
  • the cell line L- ⁇ 1B was accorded ATCC Accession No. CR 11139, on September 29, 1992.
  • ⁇ 1A Human ⁇ drenergic Receptor The entire coding region of ⁇ 1A (1401 bp), including 400 base pairs of 5' untranslated sequence (5' UT) and 200 bp of 3' untranslated sequence (3' UT), was cloned into the Kpnl site of the polylinker-modified pCEXV-3-derived eukaryotic expression vector, EXJ.RH.
  • the construct involved ligating three partial overlapping fragments: a 5' 0.6kb Hindi genomic clone, a central 1.8 EcoRI hippocampal cDNA clone, and a 3' 0.6Kb PstI genomic clone.
  • the hippocampal cDNA fragment overlaps with the 5' and 3' genomic clones so that the Hindi and Pstl sites at the 5' and 3' ends of the cDNA clone, respectively, were utilized for ligation.
  • This full- length clone was cloned into the Kpnl site of the expression vector, using the 5' and 3' Kpnl sites of the fragment, derived from vector (i.e., pBluescript) and 3'-untranslated sequences, respectively.
  • Stable cell lines were selected as described above.
  • the stable cell line expressing the human ⁇ 1A receptor used herein was designated L- ⁇ 1C (old nomenclature) and was deposited with the American Type Culture Collection, 12301 Parkiawn Drive, Rockvilie, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for tne International Recognition of the Deposit of Microorganisms for the Purposes of Patent Proce ⁇ ure
  • the cell line expressing the human ⁇ 1A receptor was accorded Accession No. CR 11140, on September 25, 1992.
  • Radioligand Binding Assays Transfected cells from culture flasks were scraped into 5ml of 5mM Tris-HCl, 5mM EDTA, pH 7.5, and lysed by soincation. The cell lysates were centrifuged at 1000 rpm for 5 min at 4°C, and the supernatant was centrifuged at 30,000 x g for 20 min at 4°C. The pellet was suspended in 50mM Tris-HCl, 1mM MgCl 2 , and 0.1% ascorbic acid at pH 7.5.
  • Binding of the ⁇ 1 antagonist [ 3 H]prazos ⁇ n (0.5 nM, specific activity 76.2 Ci/mmol) to membrane preparations of LM(tk-) cells was done in a final volume of 0.25 ml and incubated at 37°C for 20 min. Nonspecific binding was determined in the presence of 10 ⁇ M phentolamine. The reaction was stopped by filtration through GF/B filters using a cell harvester. Inhibition experiments, routinely consisting of 7 concentrations of the tested compounds, were analyzed using a non-linear regression curve-fitting computer program to obtain Ki values.
  • LM(tk-) cell lines stably transfected with the genes encoding the ⁇ 2A , ⁇ 2B , and a 2C receptors were used.
  • the cell line expressing the ⁇ 2A receptor is designated L- ⁇ 2A , and was deposited on November 6, 1992 under ATCC Accession No. CRL 11180.
  • the cell line expressing the ⁇ 2B receptor is designated L-NGC- ⁇ 2B , and was deposited on October 25, 1989 under ATCC Accession No. CRL10275.
  • the cell line expressing the ⁇ 2C receptor is designated L- ⁇ 2C , and was deposited on November 6, 1992 under ATCC Accession No. CRL-11181. Ail the cell lines were deposited with the
  • the compounds described above were assayed using cloned human alpha adrenergic receptors and the rat calcium channel.
  • the preferred compounds were found to be ⁇ 1A selective antagonists.
  • the compounds described herein were also found to exhibit weak binding affinity to the rat L-type calcium channel.
  • the alpha adrenergic receptor binding affinities of compounds 2-5, 7, 11, 13 and 14 are illustrated in Table 1 as follows:
  • optionally substituted cycloalkanone is refluxed with a diaminoalkane to form the corresponding (cycloalk-1-yl)aminoalkylimine, which on treatment with Na3O. yields (cycloalk-1-yl) aminoalkylamine.
  • the diamine is added to a 1-[(4-nitrophenyl)oxycarbonyl]pyrimidine to yield the final product.
  • cyclohexanone is shown, the process is equally applicable to substituted cycloalkanones from cyclobutanone through cyclooctanone.
  • replacement of the diaminoalkane of Part 1 with an aminoalkanol yields esters in Part 3 instead of amides.
  • Similar compounds may be produced by substitution of the 1,4-dibromobutane with other dibromoalkanes, including branched compounds in order to produce the alkyl-linked cycloalkylamine derivatives of the subject dihydropyrimidines.

Abstract

This invention is directed to dihydropyrimidine compounds which are selective antagonists for human α1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of begnin prostatic hyperplasia, impotency, cardiac arrythmia and for the treatment of any disease where the antagonism of the α1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Description

Dihydropyrimidines and Uses Thereof
This application is a continuation-in-part of PCT International Application No. PCT/US95/15025, filed November 16, 1995, the contents of which are incorporated by reference. Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
Background of the Invention The designation "α1A" is the appellation recently approved by the IUPHAR Nomenclature Committee for the previously designated "α1C" cloned subtype as outlined in the 1995 Receptor and Ion Channel Nomenclature Supplement (Watson and Girdlestone, 1995). The designation α1A is used throughout this application and the supporting tables and figures to refer to this receptor subtype. At the same time, the receptor formerly designated α1A was renamed α1D. The new nomenclature is used throughout this application. Stable cell lines expressing these receptors are described herein; however, these cell lines were deposited with the American Type Culture Collection (ATCC) under the old nomenclature (infra). Benign Prostatic Hyperplasia (BPH), also called Benign Prostatic Hypertrophy, is a progressive condition which is characterized by a nodular enlargement of prostatic tissue resulting in obstruction of the urethra. This results in increased frequency of urination, nocturia, a poor urine stream and hesitancy or delay in starting the urine flow. Chronic consequences of BPH can include hypertrophy of bladder smooth muscle, a decompensated bladder and an increased incidence of urinary tract infection. The specific biochemical, histological and pharmacological properties of the prostate adenoma leading to the bladder outlet obstruction are not yet known. However, the development of BPH is considered to be an inescapable phenomenon for the aging male population. 3PH is observed in approximately 70% of males over the age of 70. Currently, in the United States, the method of choice for treating BPH is surgery (Lepor, H., Urol. Clinics North Amer.. 17, 651 (1990)). Over 400,000 prostatectomies are performed annually (data from 1986). A medicinal alternative to surgery is clearly very desirable. The limitations of surgery for treating BPH include the morbidity rate of an operative procedure in elderly men, persistence or recurrence of obstructive and irritative symptoms, as well as the significant cost of surgery. α-Adrenergic receptors (McGrath, et. al. Med. Res. Rev., 9, 407-533, 19Θ9) are specific neuroreceptor proteins located in the peripheral and central nervous systems on tissues and organs throughout the body. These receptors are important switches for controlling many physiological functions and, thus, represent important targets for drug development. In fact, many α-adrenergic drugs have been developed over the past 40 years. Examples include clonidine, phenoxybenzamine and prazosin (treatment of hypertension), naphazoline (nasal decongestant), and apraclonidine (treating glaucoma). α-Adrenergic drugs can be broken down into two distinct classes: agonists (clonidine and naphazoline are agonists), which mimic the receptor activation properties of the endogenous neurotransmitter norepinephrine, and antagonists (phenoxybenzamine and prazosin are antagonists), which act to block the effects of norepinephrine. Many cf these drugs are effective but also produce unwanted side effects (for example, clonidine produces dry mouth and sedation in addition to its antihypertensive effects).
During the past 15 years a more precise understanding of α-adrenergic receptors and their drugs has evolved through increased scientific scrutiny. Prior to 1977, only one α-adrenergic receptor was known to exist. Between 1977 and 1988, it was accepted by the scientific community that at least two α-adrenergic receptors- -α1 and α2- -existed in the central and peripheral nervous systems. Since 1988, new techniques in molecular biology have led to the identification of at least six α-adrenergic receptors which exist throughout the central and peripheral nervous systems: α1A (new nomenclature), α1B, α1D (new nomenclature), α2A, α2B and α2C (Bylund, D.B., FASEB J., 6, 832 (1992)). In many cases, it is not known precisely which physiological responses in the body are controlled by each of these receptors. In addition, current α-adrenergic drugs are not selective for any particular α-adrenergic receptor. Many of these drugs produce untoward side effects which may be attributed to their poor α-adrenergic receptor selectivity.
Since the mid 1970's, nonselective α-antagonists have been prescribed to treat BPH. In 1976, M. Caine, et al. (Brit. J. Urol., 48, 255 (1976)), reported that the nonselective α-antagonist phenoxybenzamine was useful in relieving the symptoms of BPH. This drug may produce its effects by interacting with α-receptors lccated on the prostate. However, this drug also produces significant side effects such as dizziness and asthenia which severely limit its use in treating patients on a chronic basis. More recently, the or -adrenergic antagonists prazosin and terazosin have also been found to be useful for treating BPK . However, these drugs also produce untoward side effects. It has recently been discovered that the α1A receptor is responsible for mediating the contraction of human prostate smooth muscle (Gluchowski, C. et. al., WO 94/10989, 1994; Forray, C. et. al., Mol. Pharmacol. 45, 703, 1994). This discovery indicates that the α1A antagonists may be effective agents for the treatment of BPH with decreased side effects. Further studies have indicated that the α1A receptor may also be present in other lower urinary tract tissues, such as urethral smooth muscle (Ford et al. Br. J. Pharmacol., 114, 24P, (1995)). This invention is directed to dihydropyrimidine compounds which are selective antagonists for cloned human α1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure (Zhan, et. al. Ophthalmol. Vis. Sci., 34 Abst. #1133, 928, 1993), inhibiting cholesterol synthesis (D'Eletto and Javitt, J. Cardiovascular Pharmacol., 13 (Suppl. 2) S1-S4, 1989), benign prostatic hyperplasia, impotency (Milne and Wyllie, EP 0 459 666 A2, 1991), sympathetically mediated pain (Campbell, WO 92/14453, 1992), cardiac arrhythmia (Spiers, et. al., J. Cardiovascular Pharmacol., 16, 824-830, 1990) and for the treatment of any disease where antagonism of the α1A receptor may be useful. Summary of the Invention
This invention is directed to dihydrcpyrimidine compounds which are selective antagonists for human a1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
Detailed Description of the Invention
The present invention is directed to compounds having the structures:
Figure imgf000008_0001
Figure imgf000008_0002
Figure imgf000008_0003
Figure imgf000009_0001
or
Figure imgf000009_0002
where M has the structure
Figure imgf000009_0003
wherein each of Y1, Y2, Y3, Y, and Y5 independently may be -H; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I; -NO2; -N(R3)2; -N3; -CN; -OR3; -OCOR3; -COR3; -CON(R3)2; or -CO2R3; or wherein two of Y1, Y2, Y3, Y4 and Ys are present on adjacent carbon atoms and together constitute a methylenedioxy group; wnere R independently may oe -H; - F; straight chained or branched C1-C7 alkyl, monofluoroalkyl cr polyfluoroalkyl; straight chained or brancr.ed C2- C7 alkenyl or alkynyl; -N(R3)2; -NO2; -CN; -CO2R3; -(CH2)pPO(OR3)2; -(CH2)pPO(OR3)3; or -OR3:
where R1 may be -H; -NO2; -CN; straight chained cr branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2- C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R3)2; -OR3; -(CH2)pOR3; -COR3; -CO2R3; or -CON(R3)2, wherein any p independently is an integer from 1 to 7 inclusive; where R2 may be -H; straight chained or branched C1-C7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl , polyfluorocycloalkyl or cycloalkenyl; C3-C10 cycloalkyl-C1-C10-alkyl, C3-C10 cycloalkyl-C1-C10- monofluoroalkyl or C3-C10 cycloalkyl-C1-C10- polyfluoroalkyl; -CN; -CH2XR3, -CH2X(CH2)pNHR3, -(CH2)nNHR3, -CH2X(CH2)pN(R3)2, -CH2X(CH2)pN3, or -CH2X(CH2)pNHCXR7; or -OR3; wherein any n independently is an integer from 0 to 5 inclusive and p is as defined above; where each R3 independently may be -H; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -(CH-)pPO(OR8)2; -(CH2)pPO(OR8)3; or -(CH2}pCOOR8; where R4 has the structure
Figure imgf000011_0001
wherein 2 may be C2-C7 alkenyl or alkynyl;
CH2; O; CO; CO2; CONR3CO; CONR3; S; SO; SO2; or
NR3; m is an integer from 0 to 3 inclusive; R5 and R6 each independently may be -H; -F,
-Cl, -Br, -I; -CO2R3; -COR3; -CON(R3)2; -CN; - NO2; -N(R3)2; -OR3; straight chained or
branched C1-C7 alkyl, C1-C7 monofluoroalkyl,
C1-C7 polyfluoroalkyl, C2-C7 alkenyl, C2-C7 alkynyl, C3-C7 cycloalkyl, or C3-C7 cycloalkenyl, wherein the alkyl,
monofluoroalkyl, polyfluoroalkyl, alkenyl,
alkynyl, cycloalkyl or cycloalkenyl may be
unsubstituted or substituted with -H, aryl or
heteroaryl; aryl or heteroaryl wherein the
aryl or heteroaryl may be unsubstituted or
substituted with -H, -F, -Cl, -Br, -I, -NO2,
-CN, -N(R3)2, -OR,, -COR3, -CO2R3, or -CON(R3)2;
straight chained or branched C1-C7 alkyl,
monofluoroalkyl or polyfluoroalkyl, straight
chained or branched C2-C7 alkenyl or alkynyl,
C1-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl, or cycloalkenyl; R7 may be -H; straight chained or branched
C1-C7 alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained cr branched C2-C7 alkenyl or alkynyl; C3- C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -CN; -CO2R3; -COR3; -CON(R3)2; or -OR3; where Rθ is -H; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2- C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; where R9 may be -H; -CN; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R3)2; -OR3; -(CH2)pOR3; -COR3; -CO2R3; or -CON(R3)2; wherein X may be S; O; or NR3; and wherein B may be -H; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, alkoxy or thioalkyl; straight chained or branched
C2 - C7 alkenyl; -SCH2C6H4OR3 ; -(CH2)nC6H5;
-CH2X(CH2)nNHR3; -(CH2)nNHR3; or -OR3; or a pharmaceutically acceptable salt thereof
In the present invention aryl includes benzyl, benzoyl, naphthyl, or phenyl and heteroaryl includes pyridyl, thiophenyl, furanyl, pyrazinyl, pyrryl, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl, quinolyl, aminophenyl, benzimidazolyl or 2-keto-1-benzimidazolinyl. The compounds of the present invention may be present as enantiomers, disteriomers, isomers or two or more of the compounds may be present to form a racemic mixture Furthermore, the compounds of the present invention are preferably at least 80% pure, more preferably 90. pure, and most preferably 95% pure.
The invention further provides for the (+) enantiomer of any of the compounds described herein which is a cis isomer or trans isomer. The invention also provides for the (-) enantiomer of any of the compounds described herein which is a cis isomer or trans isomer. In one embodiment of the invention the compound is not (+)-6-(3,4-Difluorophenyl)-1-(N-[2-(4-cyano-4-phenyl-cyclohexylamino)ethyl]}carboxamιdo-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride.
Ten-fold selectivity differences are a minimum, but one skilled in the art will appreciate that compounds can be found that collectively have almost infinitely variable selective profiles. Compounds collectively having all possible combinations of selectivities are intended within the scope of this invention, provided that each of these compounds has at least a ten-fold greater affinity for the α1A receptor over the α1B and/or α1D receptors.
Preferred embodiments of the present invention include a compound selected from the group consisting of:
Figure imgf000014_0001
Figure imgf000014_0002
and
Figure imgf000014_0003
In one preferred embodiment for the compounds described herein R4 is
Figure imgf000014_0004
and p is 2, 3 or 4.
In one preferred embodiment for the compounds described herein R4 is
Figure imgf000015_0003
The invention also provides for compounds having the following structure:
Figure imgf000015_0002
In one preferred embodiment of the present invention, M is polyfluorophenyl and R5 and R6 are independently substituted or unsubstituted phenyl or pyridyl.
In a further embodiment of the present invention, R1 is -CO2CH3, -COCH3, or -CONH2, R2 is CH2OCH3, methyl or ethyl; and R6 is H, -CN, or CO2CH3.
The invention provides for the preferred embodiment having the following structures:
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000016_0002
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
and
Figure imgf000019_0002
The invention also provides for compounds having the following structure:
Figure imgf000020_0001
In another embodiment of the present invention M is
polyfluorophenyl and R5 is substituted or
unsubstituted phenyl or pyridyl.
The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the compounds described above and a pharmaceutically acceptable carrier. In the subject invention a "therapeutically effective amount" is any amount of a compound which, when administered to a subject suffering from a disease against which the compounds are effective, causes reduction, remission, or regression of the disease In one embodiment the therapeutically effective amount is an amount from about 0.01 mg per subject per day to about 500 mg per subject per day, preferably from about 0.1 mg per subject per day to about 60 mg per subject per day and most preferably from about 1 mg per subject per day to about 20 mg per subject per day. In the practice of this invention the "pharmaceutically acceptable carrier" is any physiological carrier known to those of ordinary skill in the art useful in formulating pharmaceutical compositions.
In one preferred embodiment the pharmaceutical carrier may be a liquid and the pharmaceutical composition would be in the form of a solution. In another equally preferred embodiment, the pharmaceutically acceptable carrier is a solid and the composition is in the form of a powder or tablet. In a further embodiment, the pharmaceutical carrier is a gel and the composition is in the form of a suppository or cream.
The invention provides a method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject any one of the compounds described herein effective to treat benign prostatic hyperplasia. The invention further provides that the compound additionally does not cause a fall in blood pressure at dosages effective to alleviate benign prostatic hyperplasia. In one preferred embodiment the compound effects treatment of benign prostatic hyperplasia by relaxing lower urinary tract tissue and in particular where the lower urinary tract tissue is prostatic smooth muscle.
The invention further provides a method of treating a subject suffering from elevated intraocular pressure which comprises administering to the subject one of the compounds described herein effective to lower intraocular pressure. The invention further provides a method of treating a subject suffering from a disorder associated with elevated blood cholesterol which comprises administering to the subject one of the compounds described herein effective to inhibit cholesterol synthesis.
The invention also provides a method of treating a disease which is susceptible to treatment by antagonism of the α1A receptor which comprises administering to the subject one of the compounds described herein effective to treat the disease.
The invention further provides a method of treating a subject suffering from impotency which comprises administenng to the subject one of the compounds described herein effective to treat impotency.
The invention further provides a method of treating a subject suffering from sympathetically mediated pair, which comprises administering to the subject one of the compounds described herein effective to treat sympathetically mediated pain. The invention provides a method of treating a subject suffering from cardiac arrhythmia which comprises administering to the subject one of the compounds described herein effective to treat cardiac arrhythmia. This invention also provides a method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of any of the compounds described above in combination with a 5 alpha-reductase inhibitor effective to treat benign prostatic hyperplasia. Preferably, the 5-alpha reductase inhibitor is finasteride. The dosage administered to the subject is about 0.01 mg per subject per day to 50 mg per subject per day of finasteride in combination with an α1A antagonist. A preferred dosage administered to the subject is about 0.2 mg per subject per day to 10 mg per subject per day of finasteride in combination with an α1A antagonist. A more preferred dosage administered to the subject is about 1 mg per subject per day to 7 mg per subject per day of finasteride in combination with an α1A antagonist. The most preferred dosage administered to the subject is about 5 mg per subject per day of finasteride in combination with an α1A antagonist. The invention also provides for a pharmaceutical composition comprising a therapeutically effective amount of a combination of any of the compounds described herein in combination with finasteride and a pharmaceutically acceptable carrier. In one embodiment tne pnarmaceutical composition is a therapeutically effective amount of a combination comprising an amount from about 0.01 mg per subject per day to about 500 mg per subject per day of any one of the compounds αescnoed herein and an amount cf finasteride of about 5 mg per subject per day. A more preferred embodiment of the pharmaceutical composition is a therapeutically effective amount of a combination comprising an amount from about 0.1 mg per subject per day to about 60 mg per subject per day of any one of the compounds described herein and an amount of the finasteride of about 5 mg per subject per day. The most preferred embodiment of the pharmaceutical composition is a therapeutically effective amount of a combination comprising from about 1 mg per subject per day to about 20 mg per subject per day of any one of the compounds described herein and an amount of the finasteride of about 5 mg per subject per day. The invention further provides a method of relaxing lower urinary tract tissue which comprises contacting the lower urinary tract tissue with an amount of one of the compounds described herein effective to relax lower urinary tract tissue. In one embodiment the lower urinary tract tissue is prostatic smooth muscle. In one preferred embodiment the compound additionally does not cause a fall in blood pressure when it is effective to relax lower urinary tract tissue. The invention provides a method of relaxing lower urinary tract tissue in a subject which comprises administering to the subject an amount of one of the compounds described herein effective to relax lower urinary tract tissue. In one preferred embodiment the compound does not cause a fall in blood pressure and the lower urinary tract tissue is prostatic smooth muscle.
The invention further provides for a method of innibiting contraction of prostatic tissue, which comprises administering to the subject an amount of any of the compounds described herein effective to inhibit contraction of prostatic tissue. In one preferred em.Dodiment the prostatic tissue is prostatic smooth muscle and the compound additionally does not cause a fall in blood pressure.
The invention provides for the use of the compounds described herein for the preparation of a pharmaceutical composition for lowering intraocular pressure, inhibiting cholesterol synthesis, and the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the α1A receptor may be useful. The invention provides for the use of the compounds described herein for the preparation of a pharmaceutical composition for relaxing lower urinary tract tissue and in particular prostatic smooth muscle. The invention further provides for the use of any of compounds described herein for the preparation of a pharmaceutical composition, where the compound additionally does not cause a fall in blood pressure at dosages effective to lower intraocular pressure, to inhibit cholesterol synthesis, and for the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the α1A receptor may be useful. The invention provides for the use of the compounds described herein in the preparation of a medicament for lowering intraocular pressure, inhibiting cholesterol synthesis, and for the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the α1A receptor may be useful. The invention provides for the use of the compounds described herein in the preparation of a medicament for relaxing lower urinary tract tissue and in particular prostatic smooth muscle. The invention further provides for the use of any of compounds described herein in the preparation of a medicament, where the compound additionally does not cause a fall in blood pressure at dosages effective to lower intraocular pressure, to inhibit cholesterol syntnesis, and for the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the α1A receptor may be useful. The invention provides for a drug which is useful for lowering intraocular pressure, inhibiting cholesterol synthesis, and the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the α1A receptor may be useful, the effective ingredient of the said drug being any of the compounds described herein. The invention further provides the drug described herein additionally does not cause a fall in blood pressure at dosages effective to lower intraocular pressure, to inhibit cholesterol synthesis, and for the treatment of: benign prostatic hyperplasia, impotency, cardiac arrhythmia and any disease where antagonism of the α1A receptor may be useful. The invention provides for a drug which is useful for relaxing lower urinary tract tissue and in particular prostatic smooth muscle, the effective ingredient of the drug being any of the compounds described herein. The invention further provides the drug which is useful for relaxing lower urinary tract tissue additionally does not cause a fall in blood pressure at dosages effective to relax lower urinary tract tissue.
The invention also provides for the (-) and (+) enantiomers of all compounds of the subject application described herein. Included in this invention are pharmaceutically acceptable salts and complexes of all of the compounds described herein. The salts include but are not limited to the following acids and bases. The following inorganic aciαs, nydrocnloric acid, hydrofluoric acid, hydronromic acid, hydroiodic acid, sulfuric acid and boric acid The organic acids, acetic acid, trifluoroacetic acid, formic acid, oxalic acid, malonic acid, succiinc acid, fumaric acid tartaric acid, maleic acid, citric acid, methanesulfoinc acid, trifluoromethanesulfonic acid, benzoic acid, glycolic acid, lactic acid and mandelic acid. The following inorganic bases; ammonia, hydroxyethylamine and hydrazine. The following organic bases, methylamine, ethylamine, propylamine, dimethylamine, diethylamine, trimethylamine, triethylamine, ethylenediamine, hydroxyethylamine, morpholine, piperazine and guanidine. This invention further provides for the hydrates and polymorphs of all of the compounds described herein.
In one preferred embodiment the pharmaceutical carrier may be a liquid and the pharmaceutical composition would be in the form of a solution. In another equally preferred embodiment, the pharmaceutically acceptable carrier is a solid and the composition is in the form of a powder or tablet. In a further embodiment, the pharmaceutical carrier is a gel and the composition is in the form of a suppository or cream. In a further embodiment the compound may be formulated as a part of a pharmaceutically acceptable transdermal patch.
A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suicacle proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium pnosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmoregulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil) . For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellent. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by for example, intramuscular, intrathecal, epidural, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compounds may be prepared as a sterile solid composition which may be dissolved or suspended at the time of administration using sterile water, saline, cr other appropriate sterile injectable medium. Carriers are intended to include necessary and inert binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
The compound can be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents, for example, enough saline or glucose to make the solution isotonic, bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
The compound can also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular compound in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of administration. This invention further provides for metabolites of the compounds of the present invention. The in vivo activities and mechanisms of action of numerous enzymes responsiole for the generation of metabolites of pharmaceutical compounds are well-known in the art. For example, ethers may be modified to alcohols, esters may be modified by esterases, or amides may be modified by amidases and peptidases.
This invention further provides a prodrug of the compounds disclosed herein. Knowledge of metabolic activities allows the design of prodrug compounds which, when administered to a
subject, such as a human, are expected to yield metabolites which include the compounds of the present invention. For example, the cyclohexylamino nitrogen may be modified by various substituents, such as methyl, alkanoyl, aroyl, or an alkyl or aryl carbamate may be formed, which are expected to yield the compounds of the present invention when acted upon in vivo by endogenous enzymes. As stated above, such modifications are intended only as
illustrative examples, and are not intended to limit the scope of the present invention, as such modifications and techniques therefore are well-known in the art.
One skilled in the art will readily appreciate tnat appropriate biological assays will be used to determine the tnerapeutic potential of the claimed compounds for treating the aoove noted disorders.
This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.
Experimental Details
For Examples 1-17 Scheme 1 illustrates the general synthetic scheme for the preparation of the compounds of the present invention. Specific references to synthetic steps from Schemes 2-8 are included in the Examples below where appropriate. All NMRs were obtained using a 300 MHz GE QEPLUS NMR machine.
Example 1
cis-6-(3,4-Difluorophenyl)-1-{N-[2-(4-cyano-4-phenylcyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride.
Part-1
a) General procedure for 2-[4-Cyano-4-arylcyclohexylamino]ethylamine
(Scheme 2; Part-1).
A mixture of 4-cyano-4-aryl-cyclohexanone (48.7 mmol) and ethylenediamine (8.78 g, 146 mmol) and p- toluenesulfonic acid (92 mg) in benzene (200 mL) was refluxed for 4 h in Dean-Stark trap to remove the water that formed. Solvent was evaporated and the residue was redissolved in methanol (60 mL) and cooled to 0 °C. Sodium borohydride (6.4 5 g) was added in portions and the mixture was stirred at room temperature for 3 h. Solvent was evaporated, the residue was dissolved in dichloromethane (300 mL), washed with brine (3 × 500 mL), dried (potassium carbonate), and the solvent evaporated to leave the product as a pale yellow viscous oil (90-95%). The product was found to contain the cis/ trans isomers in the ratio of about 9:1. Careful chromatography of this mixture with chloroform/methanol/2M ammonia in methanol (100/10/5 to 100/20/10) yielded several some earlier fractions enriched in the trans isomer with respect to the amino and cyano groups. Later fractions eluted contained almost pure cis isomer relative to the amino and cyano groups.
Part-2
b) Methyl 2-{(3,4-difluorophenyl)methylene}-3-oxobutyrate (Scheme 2; Step C). A mixture of 3,4-difluorobenzaldehyde (14.2 g, 0.1 mol), methyl acetoacetate (12.2 g, 0.105 mol), piperidine (0.430 g, 5 mmol), and acetic acid (0.30 g, 5 mmol) in benzene (150 mL) was stirred and refluxed with a Dean-Stark trap for 8 hours. Benzene was evaporated, the residue was dissolved in ethyl acetate (200 mL) and washed with brine (50 mL), saturated potassium bisulfate solution (50 mL), and saturated sodium bicarbonate solution in sequence. The ethyl acetate solution was dried (magnesium sulfate), solvent removed under reduced pressure and the residue was purified by column chromatography (SiO2, EtOAc/hexane, 10% -15%). The product, methyl 2-{(3,4-difluorophenyl)methylene}-3¬oxobutyrate, was obtained as a yellow oil (0.98 g, 98.3%) and was used in the next step without any further characterization. c ) 6 - ( 3 , 4 -Dif luorophenyl) - 1 , 6 -dihydro- 2 -methoxy- 5 -methoxycarbonyl-4-methylpyrimidine (Scheme 2 ; Step D). A mixture of methyl 2-{(3,4-αifluorophenyl)methylene}-3-oxobutyrate (8.8 g, 36.6 mmol), O-methylisourea hydrogen sulfate (9.4 g, 55 mmol), and NaHCO3 (12.3 g, 0.146 mol) in DMF (30 mL) was stirred and heated at 70 °C for 16 hours. The mixture was cooled, diluted with EtOAc (300 mL) and washed with water (5 × 300 mL), brine (300 mL), and dried (MgSO4). Solvent was evaporated and the crude product was purified by flash column chromatography on silica gel using 10% through 20% EtOAc in hexane as the gradient eluent, to leave the product as an oil (3.82 g, 30.2%). d) 6-(3,4-Difluorophenyl)-1,6-dihydro-2-methoxy-5-methoxycarbonyl-4-methyl-1-[(4-nitrophenyloxy)carbo nyl]pyrimidine (Scheme 2; E).
To a solution of 6-(3,4-difluorophenyl)-1,6-dihydro-2-methoxy-5-methoxycarbonyl-4-methylpyrimidine (2.82 g, 9.52 mmol) and 4-dimethylaminopyridine (1.16 g, 9.52 mmol) in CH2Cl2 (50 mL) , at 0-5 °C, 4-nitrophenyl chloroformate (1.82 g, 9.04 mmol) was added and the mixture was allowed to warm to room temperature. After 12 hours solvent was evaporated and the residue was purified by flash column chromatography (SiO2, EtOAc/hexane, 10%-15%)to obtain the product as white crystals (3.72, 84.7%); m.p. 172-174 °C. e) 6-(3,4-Dlfluorophenyl)-1,2,3,6-tetrahydro-2-oxo-5- methoxycarbonyl-4-methyl-1-(4-nitrophenoxy)
carbonylpyrimidine (Scheme 2; Step F).
To a well stirred solution of 6-(3,4-difluorophenyl)- 1,6-dihydro-2-methoxy-5-methoxycarbonyl-4-methyl-1-(4- nitrophenoxy)carbonylpyrimidine (10 g) in TTTF (200 mL) at room temperature was added aqueous 6N hydrochloric acid (10 mL). The stirring was continued for 3 h. Solvent was evaporated and the residue was dried under vacuum to obtain the product as a white powder (9.7 g, 100%); m.p. 185-186 °C. Part-3
f) cis-6-(3,4-Difluorophenyl)-1-{N-[2-(4-cyano-4-p h e n y l cyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride (Scheme 2; Step G). A solution of 5-methoxycarbonyl-4-methyl-1,2,3,6-tetrahydro-2-oxo-6-(3,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (500 mg, 1.15 mmol) and cis-2-[4-cyano-4-phenyl-cyclohexylamino]ethylamine (351 mg, 1.5 mmol) in dichloromethane (50 mL) was stirred at room temperature for 12 hours. The solution was washed with ice-cold 0.5N NaOH (2 × 10 mL) and dried over sodium sulfate. Solvent was evaporated at reduced pressure and the residue was purified by flash chromatography on silica gel (dichloromethane:MeOH:2M ammonia in MeOH, 90:8:4) to give 0.55 g (87%) as a white powder. The HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether. M.P. 172-174°C; Anal. Calcd. for C29H31N5O4F2Cl .1.3H2O: C, 56.96; H,
5.70; N, 11.45. Found: C, 57.10; H, 5.69; N, 11.12.
Example 2
cis-6-(3,4,5-Trifluorophenyl)-1-{N-[2-(4-cyano-4-phenyl - cyc l ohexyl amino ) e thyl ] } -carboxamido-5-acetyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride a) 3-{(3,4,5-Trifluorophenyl)methylene}-2,4-pentanedione (Scheme 2; Step C). A mixture of 3,4,5-trifluorobenzaldehyde (4.2 g, 26.2 mmol), 2,4-pentanedione (2.62 g, 26.2 mmol), piperidine (0.430 g, 5 mmol) in benzene (150 mL) was stirred and refluxed with a Dean-Stark trap for 8 hours. Benzene was evaporated and the yellow oily residue, 2-{(3,4,5- trifluorophenyl)methylene}-2,4-pentanedione, was used in the next step without any further purification. b) 6-(3,4,5-Trifluorophenyl)-1,6-dihydro-2-methoxy-5-acetyl-4-methylpyrimidine (Scheme 2; Step D). A mixture of 2-{(3,4,5-trιfluorophenyl)methylene}-2,4-pentanedione (26.2 mmol), O-methylisourea nydrogen sulfate (3.22 g, 39.3 mmol), and NaHCO, (6.6 g, 78.6 mmol) in EtOH (400 mL) was stirred and heated at 95-100 °C for 6 hours. The mixture was filtered and the solid residue was washed with ethanol (100 mL). Solvent was evaporated from the combined filtrate and the crude product was purified by flash column chromatography on silica gel using 10% through 25% EtOAc in hexane as the gradient eluent, to leave the product as an oil (2.80 g, 36%). c) 6-(3,4,5-Trifluorophenyl)-1,6-dihydro-2-methoxy-5 - acetyl-4 -methyl- 1- [ (4-nitrophenyloxy) carbonyl] pyrim idine (Scheme 2; Step E).
To a solution of 6-(3,4,5-trifluorophenyl)-1,6-dihydro-2-methoxy-5-acetyl-4-methylpyrimidine (2.8 g, 9.38 mmol) and pyridine (10 mL) in CH2Cl2 (200 mL) at 0-5 °C was added 4-nitrophenyl chloroformate (1.886 g, 9.38 mmol) and the mixture was allowed to warm to room temperature. After 12 hours solvent was evaporated and the residue was purified by flash column chromatography (SiO2, dichloromethane/EtOAc, 10%-15%) to obtain the product as a white powder (4.0 g, 92%). d) 6-(3,4,5-Trifluorophenyl)-1,2,3,6-tetrahydro-2-oxo- 5-acetyl-4-methyl-1-[(4-nitrophenyloxy)carbonyl]pyrim idine (Scheme 2; Step F).
To a well-stirred solution of 6-(3,4,5-trifluoro phenyl)-1,6-dihydro-2-methoxy-5-acetyl-4-methyl-1- [(4-nitrophenyloxy)carbonyl]pyrimidine (4.0 g, 8.63 mmol) in THF (100 mL) at 0-5 °C, 6N aqueous HCl (4 mL) was added and the mixture was allowed to warm to room temperature. After 2 h, solvent was evaporated and the product dried under vacuum. The title compound was ootained as a pure single component and used un the next step without further purification (3.88 g, 100%). e) cis-6-(3,4,5-Trifluorophenyl)-1-{N-[2-(4-cyano-4-pheny l - cyc l ohexy l ami no ) e t hy l ] } -carboxamido-5-acetyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride (Scheme 2 ; Step G).
A mixture of 6-(3,4,5-trifluorophenyl)-1,2,3,6-tetra hydro-2-oxo-5-acetyl-4-methyl-1-[(4-nitrophenyloxy) carbonyl] pyrimidine (44.9 mg, 0.1 mmol) and cis-2-(4-cyano-4-phenyl-cyclohexylamino)ethylamine (23.4 mg, 0.23 mmol) in THF (10 mL) was stirred at room temperature for 10 h and the solvent evaporated. The residue was redissolved in dichloromethane (10 mL), washed with ice-cold 0.5 N NaOH (2 × 5 mL), dried and solvent evaporated. The residue was purified by preparative thin layer chromatography on silica gel using chloroform-methanol-2M ammonia in methanol (100/2/1) as the eluent to afford the product as a white powder (53 mg, 88%). The HCl salt was prepared by treatment with 1N HCl in ether to give the product as a white powder. Anal. Calcd. for C30H32N5O3ClF3 0.5CH2Cl2: C, 56.66; H, 5.30; N, 10.83. Found: C, 56.51; H, 5.12; N, 11.09.
Example 3
(+)-cis-5-Carboxamido-6-(2,4-difluorophenyl)-1-{N- [ 2 - ( 4 - c y a n o - 4 - p h e n y l cyclohexylamino)ethyl]}carboxamido-4-ethyl-2-oxo- 1,2,3,6-tetrahydropyrimidine hydrochloride . a) Benzyl 2-[(2,4-difluorophenyl)
methylene]-3-oxopentanoate (Scheme 2; Step C) . A solution of benzyl propionylacetate (157 g, 0.758 mol),
2, 4-difluorobenzaldehyde (107.65 g, 0.758 mol), and piperidinium acetate (5.49 g, 38 mmol) in benzene (1 L) were stirred at room temperature for 96 h. The mixture was washed with water (2 × 100 mL), dried (magnesium sulfate) and the solvent evaporated under reduced pressure to yield the product as a pale yellow syrup (251.2 g) which was used in the next step without further purification. b) 5-(Benzyloxycarbonyl)-1,6-dihydro-2-methoxy-4-ethyl-6-(2,4-difluorophenyl)pyrimidine (Scheme 2; Step D) . A suspension of benzyl 2-[(2,4-difluorophenyl)
methylene]-3-oxopentanoate (80.0 g, 0.241 mol), O-methylisourea hemisulfate (63.8 g, 0.362 mol, 1.5 eq.), NaHCO3 (60.48 g, 0.72 mol) in ethanol (800 mL) was stirred at 60-70 °C for 20 h. After cooling to room temperature, the mixture was filtered, and the solid was washed with ethanol (200 mL) . The solvent was evaporated from the combined filtrates and the residue was purified by column chromatography (SiO2, EtOAc/Hexane, 10%-30%) to yield 5-(benzyloxycarbonyl)-1,6-dihydro-2-methoxy-4-ethyl-6-(2,4-difluorophenyl)pyrimidine as a pale yellow oil (39 g, 42%). 1H-NMR analysis showed the product to be a mixture of amine/imine tautomers, which was used as is in the next step. c) 5-(Benzyloxycarbonyl)-4-ethyl-1,6-dihydro-2-methoxy- 6-(2,4-difluorophenyl)-1-[(4-nitrophenyloxy)
carbonyl]pyrimidine (Scheme 2; Step F). To a well stirred solution of 5-(benzyloxycarbonyl)-1,6-dihydro- 2-methoxy-4-ethyl-6- (2,4-difluorophenyl)pyrimidine
(22.5 g, 59.3 mmol) and 4-(N,N-dimethylamino)pyridine (9.3 g, 75.8 mmol) in CH2Cl2 (200 mL) was added powdered 4-nitrophenyl chloroformate (15.3 g, 75.8 mmol) at 0 °C. The reaction mixture was stirred for 12 h at room temperature and then water (50 mL) was added. The pH of the aqueous layer was adjusted to 10-11 by the addition of 6 N sodium hydroxide. The dichloromethane layer was separated and dried (Na2SO4) . Solvent was evaporated in vacuo and the residue was purified by column chromatography (SiO2, dichloromethane/hexane, 20%-50%) to yield the product as a viscous oil (32.0 g, 98%). d) 5-(Benzyloxycarbonyl)-4-ethyl-1,6-dihydro-1-{N-[2-phenyl)ethyl]}carboxamido-2-methoxy-6-(2,4-difluoro phenyl)pyrimidine (Scheme 3; Steps C-1 & C-2). To a stirred solution of 5-(benzyloxycarbonyl)-4-ethyl-1,6-dihydro-2-methoxy-6-(2,4-dιfluorophenyl)-1- [(4-nitrophenyloxy)carbonyl]pyrimidine (32 g, 58.17 mmol) in dichloromethane (200 mL) was added R- (+)-α-methylbenzylamine (9.16, 75.6 mmol) at room temperature. The mixture was stirred for 12 h and then was diluted with more dichloromethane (200 mL) and washed with 0.5 N NaOH solution (2 × 60 mL). The organic layer was dried over Na2SO4, filtered and solvent was evaporated. The resulting mixture of diastereomers was separated by column chromatography (SiO2, 3% EtOAc in toluene). The first major product to elute was (+)-5-(benzyloxycarbonyl)-4-ethyl-1,6-dihydro-1-{N-[2-phenyl)ethyl]}carboxamido-2-methoxy-6- (2,4-difluorophenyl)pyrimidine (12.15 g, 38%). [α]D = +214 (c = 1.5 g in 100 mL CHCl3). e) (+)-5-(Benzyloxycarbonyl)-1,6-dihydro-2-methoxy-4-ethyl-6-(2,4-difluorophenyl)pyrimidine (Scheme 3; Step C-3). To a stirred solution of (+)-5(benzyloxycarbonyl) -4-ethyl-1,6-dihydro-1-{N-[2-phenyl)ethyl]}carboxamido- 2-methoxy-6-(2,4-difluorophenyl)pyrimidine (11.15 g, 20.41 mmol) in toluene (250 mL) was added 1,8-diazabicyclo[5,4,0]-undec-7-ene (4.04 g, 26.53 mmol) and the mixture was stirred at room temperature for 14 h. The solvent was evaporated and the residue was purified by flash column chromatography on silica gel with 3:1 EtOAc/hexane as eluent to give (+)-5- (benzyloxycarbonyl)-1,6-dιhydro-2-methoxy-4-ethyl-6-(2,4-difluorophenyl)pyrimidine as a viscous oil (6.15 g, 78%). f) (+)-5-(Benzyloxycarbonyl)-4-ethyl-1,6-dihydro-2-methoxy-6-(2,4-difluorophenyl)-1-[(4-nitrophenyl
-oxy)carbonyl]pyrimidine (Scheme 2; Step E). To a well stirred solution of (+)-5-(benzyloxycarbonyl)-1,6-dihydro-2-methoxy-4-ethyl-6-(2,4-difluorophenyl)pyrimidine (4.1 g, 10.62 mmol) and 4-(N,N-dimethylamino)pyridine (1.69 g, 13.80 mmol) in CH2Cl2
(200 mL) was added solid 4-nitrophenyl chloroformate
(2.78 g, 13.80 mmol) at room temperature. The reaction mixture was stirred for 12 h and washed with 0.5 N NaOH solution (2 × 50 mL). The organic layer was separated and dried (Na2SO4). The solvent was evaporated and the residue was purified by column chromatography on silica gel using dichloromethane/hexane (20%-50%) as the eluent to give (+) -5-(benzyloxycarbonyl)-4-ethyl-1,6-dihydro-2-methoxy-6-(2,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (5.37 g, 92%) as a viscous oil. g) (+)-5-Benzyloxycarbonyl-4-ethyl-1,2,3,6-tetrahydro-2-oxo-6-(2,4-difluorophenyl)-1-[(4-nitrophenyloxy) carbonyl]pyrimidine (Scheme 4; Step A).
To a solution of (+)-6-(2,4-difluorophenyl)-1,6- dihydro-2-methoxy-5-benzyloxycarbonyl-4-ethyl-1-(4- nitrophenoxy)-carbonylpyrimidine (6.50 g, 11.81 mmol) in dichloromethane (150 mL) at room temperature was added 1N HCl in ether (50 mL) and the mixture was stirred at room temperature for 12 hours. Solvent was evaporated at reduced pressure and the residue was dried to give 6.31 g (100%) of the product as a white powder . h) ( + ) - 5 - (Benzyloxycarbonyl) - 6 - (2 , 4-difluorophenyl) -4 - ethyl-2-oxo-1,2,3,6-tetrahydro-1-{N-[2-(4-cyano-4-phenyl-cyclohexylamino)ethyl]}carboxamidopyrimidine (Scheme 4; Step B-1).
A mixture of (+)-5-benzyloxycarbonyl-4-ethyl-1,2,3,6-tetrahydro-2-oxo-6-(2,4-difluorophenyl!-1- [(4-nitrophenyloxy)carbonyl]pyrimidine (537 mg, l mmol) and cis-2-(4-cyano-4-phenyl-cyclohexylamino)ethylamine (281 mg, 1.2 mmol) in THF (20 mL) was stirred at room temperature for 10 h and the solvent evaporated. It was redissolved in dichloromethane (10 mL), washed with ice-cold 0.5 N NaOH (2 X 5 mL), dried and solvent evaporated. The residue was purified by preparative thin layer chromatography on silica gel using chloroform-methanol-2M ammonia in methanol (100/2/1) as the eluent to afford the product as a white powder (603 mg, 94%). i) (+)-6-(2,4-Difluorophenyl)-4-ethyl-2-oxo-1,2,3,6-tetrahydro-1-{N- [2- (4-cyano-4-phenylcyclohexylamino)ethyl]}carboxamidopyrimidine-5-carboxylic acid (Scheme 4; Step B-2).
To a suspension of 10% Pd-C (100 mg) in MeOH (40 mL) and H2O (8 mL) was added a solution of (+)-5- (benzyloxycarbonyl)-6-(2,4-difluorophenyl)-4-ethyl-2-oxo-1,2,3,6-tetrahydro-1-(N-[2-(4-cyano-4-phenylcyclohexylamino)-ethyl]}carboxamidopyrimidine (320 mg, 0.5 mmol) in methanol (10 mL) and the mixture was hydrogenated at 80 psi for 6 h. The black suspension was filtered through a pad of celite and washed thoroughly with MeOH (2.0 L) and methanol/chloroform (1:2, 200 mL) . Solvent was evaporated from the combined filtrate to yield the product (+)-cis-6-(2,4- difluorophenyl)-4-ethyl-2-oxo-1,2,3,6-tetrahydro- 1 - { N - [ 2 - ( 4 - c y a n o - 4 - p h e n y l cyclohexylamino)-ethyl]}carbox
amidopyrimidine-5-carboxylic acid as a white solid (276 g, 98%). The product was used in the next step without further purification. j ) ( + ) - cis - 5 - Carboxamido - 6 - ( 2 , 4 -difluorophenyl) -1-{N- [2- (4-cyano-4-phenylcyclohexylamino)ethyl]}carboxamido-4-ethyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride (Scheme 4; Step B-3).
A mixture of (+)-cis-6-(2,4-difluorophenyl)-4-ethyl-2-oxo-1,2,3,6-tetrahydro-1-(N-[2-(4-cyano-4-phenylcyclohexylamino)ethyl] }carboxamidopyrimidine-5-carboxylic acid (141 mg, 0.25 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodιimιde hydrochloride (71.3 mg, 0.372 mmol), and 4-(N,N-dimethylamino)pyridine (45.4 mg, 0.372 mmol) in anhydrous dichloromethane (30 mL) was stirred at room temperature for 2 h. 40% Aqueous ammonia (4090, 0.5 mL) was added to this mixture and the stirring was continued for 12 h. The mixture was diluted with 20 mL of dichloromethane and washed with saturated aqueous ammonium chloride solution (3 × 10 mL). Solvent was evaporated from the dried (sodium sulfate) dichloromethane solution and the residue was purified by column chromatography on silica gel using chloroform-methanol-2M ammonia in methanol (100/2/1) as the eluent, to obtain the desired product as a white powder (120 mg, 88%); [α]D = +107 (c = 1.38 g, dichloromethane). The HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether. M.p. 225-228 °C; Anal. Calcd. for C29H33N6O3F2Cl.0.38H2O.0.19CH2Cl2:C, 57.47; H, 5.64; N, 13.75. Found: C, 57.80; H, 5.56; N, 13.37.
Example 4
( +) -cis-6-(3,4-Difluorophenyl)-1-{N- [2-(4-cyano-4- p h e n y l cyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl- 4-methoxymethyl-2-oxo-l,2,3,6-tetrahydropyrimidine hydrochloride
Part-2
a) Methyl 2-[(3,4-difluorophenyl)methylene]-3-oxo-4-methoxybutyrate (Scheme 2; C).
To a solution of methyl 4-methoxyacetoacetate (84.32 g, 0.577 mol), 3,4-difluorobenzaldehyde (82 g, 0.577 mmol), and piperidinium acetate (5.86 g, 0.068 mol) in benzene (1.5 L) were added molecular sieves (400 g) ana the mixture was stirred at room temperature for 48 h. The molecular sieves were removed by filtration and the solvent was evaporated from the filtrate under reduced pressure. The residue was purified by column chromatography on silica gel using chloroform/ethyl acetate (100:3) to get the product as an oil (67 g, 47%). This product was a mixture of cis and trans isomers. b) 5-Methoxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine (Scheme
2; Step D). A suspension of methyl 2-[(3,4-difluorophenyl)methylene]-3-oxo-4-methoxybutyrate (7.50 g, 27.75 mmol), O-methylisourea hemisulfate (7.17 g, 41.63 mmol, 1.5 eq.), and sodium bicarbonate (6.99 g, 83.25 mmol, 3 eq.) in ethanol (400 mL) was stirred at 50-55°C for 6 h. The solvent was evaporated from the combined filtrates and the residue was purified by column chromatography (SiO2, EtOAc/hexane, 10% -30%) to give 5-methoxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine as a pale yellow oil (4.3 g, 47%). c) 5-Methoxycarbonyl-4-methoxymethyl-1,6-dihydro-2-methoxy-6- (3 ,4-difluorophenyl) -1- [ (4-nitrophenyloxy)carbonyl]pyrimidine (Scheme 3; Step B).
To a well stirred solution of 5-methoxycarbonyl-1,6- dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluoro pnenyl) pyrimidine .4.3 g, 13.18 mmol) and 4-(N,N-dimethylamιno)pyridine (2.09 g, 17.13 mmol) in CH2Cl2 (100 mL) was added solid 4 -nitrophenyl chloroformate 13.45 g, 17.13 mmol) at 0 °C. The reaction mixture was stirred for 12 h at room temperature and the solid formed was removed by filtration. Solvent was evaporated from the filtrate and the residue was purified by column chromatography (SiO2, dichloromethane/hexane, 20% -50%) to yield the product as a viscous oil (3.85 g, 59%). d) 5-Methoxycarbonyl-4-methoxymethyl-1,6-dihydro-1-{N- [2-phenyl)ethyl]}carboxamido-2-methoxy-6-(3,4-difluorophenyl)pyrimidine (Scheme 3; Steps C-1 & C-2). To a stirred solution of 5-methoxycarbonyl-4-methoxymethyl-1,6-dihydro-2-methoxy-6- (3,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]
pyrimidine (3.82 g, 7.77 mmol) in THF (140 mL) was added R- (+)-α-methylbenzylamine (1.13 g, 9.33 mmol, 1.2 eq.) at room temperature and the stirring was continued for 12 h. Solvent was evaporated and the residue was purified by column chromatography (SiO2, 10-20% EtOAc in hexane). The first major product to elute was (+)-5-methoxycarbonyl-4-methoxmethyl-1,6-dihydro-1-{N-[2-phenyl)ethyl] }carboxamido-2-methoxy-6- (3,4-difluorophenyl)pyrimidine (1.74 g, 44.5%), as an oil. [α]D = +205.5 (c = 5.1 g in 100 mL CHCl3). e) (+)-5-Methoxycarbonyl-1,6-dihydro-2-methoxy-4- methoxymethyl-6-(3,4-difluorophenyl)pyrimidine (Scheme
3; Step C-3).
To a stirred solution of (+)-5-methoxycarbonyl-4- methoxymethyl-1,6-dihydro-1-{N-[2-phenyl)ethyl]} carboxamido-2-methoxy-6-(3,4-difluorophenyl)pyrimidine (1.74 g, 3.67 mmol) in toluene (40 mL) was added 1,8- diazabicyclo[5,4,0]-undec-7-ene (0.250 g, 1.64 mmol) and the mixture was stirred at 70-80 °C for 1.5 h. Solvent was evaporated and the residue was purifiec oy flash column chromatography on silica gel with 9:1 CHCl3/EtOAc as eluent to give (+)-5-methoxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluoro phenyl)pyrimidine as a viscous oil (1.11 g, 92.5%) f) Chiral HPLC separation of (+)-5-Methoxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine (Scheme 3; Step A).
The racemic 5-methoxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine was resolved by chiral HPLC [Chiralcel OD 20 × 250 mm #369-703-30604; λ 254 nm; hexanes/ethanol 95/5 and 0.01% diethylamine; 60 mg per injection; retention time of the desired enantiomer: 10.80 min., the first enantiomer peak to elute] to give (+)-5-methoxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine. g) (+)-5-Methoxycarbonyl-4-methoxymethyl-1,6-dihydro-2-methoxy-6-(3,4-difluorophenyl)-1-[(4-nitrophenyl oxy)carbonyl]pyrimidine (Scheme 2; Step E).
To a well stirred solution of (+)-5-methoxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6- (3,4-difluorophenyl)pyrimidine (1.11 g, 3.4 mmol) and 4- (N,N-dimethylamino)pyridine (0.54 g, 4.42 mmol) in CH2Cl2 (200 mL) was added powdered 4-nitrophenyl chloroformate (0.891 g, 4.42 mmol) at room temperature. Solvent was evaporated and the residue was purified by column chromatography on silica gel using CHCl3/EtOAc
(20%-50%) as the eluent to give (+)-5-methoxycarbonyl-4-methoxymethyl-1,6-dihydro-2-methoxy-6- (3,4-diflurophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine
(1.30 g, 78%) as a viscous oil. [α]D = +262.2 (c = 2.3 g in 100 mL CHCl3). h) (+)-5-Methoxycarbonyl-4-methoxymethyl-1,2,3,6- tetrahydro-2-oxo-6-(3,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (Scheme 2; Step F).
To a solution of (+)-6-(3,4-difluorophenyl)-1,6-dihydro-2-methoxy-5-methoxycarbonyl-4-methoxymethyl-1- (4-nitrophenoxy)-carbonylpyrimidine (0.305 g, 0.60 mmol) in dichloromethane (15 mL), 1N HCl in ether (6 mL) was added at room temperature and the mixture was stirred at room temperature for 12 hours. Solvent was evaporated at reduced pressure and the residue was dried to give 0.295 g (100%) of the product as a white powder.
Part-3
i) (+)-cis-6-(3,4-Difluorophenyl)-1-{N-[2-(4-cyano-4-p h e n y l
cyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride (Scheme 2; Step G). A solution of (+)-5-methoxycarbonyl-4-methoxymethyl-1,2,3,6-tetrahydro-2- oxo-6-(3,4-difluorophenyl)-1-[(4-nitrophenyloxy) carbonyl]pyrimidine (0.850 g, 1.73 mmol) and cis-2-(4- cyano-4-phenyl-cyclohexylamino)ethylamine (0.567 g,
2.42 mmol) in dichloromethane (50 mL) was stirred at room temperature for 12 hours. It was washed with ice- cold 0.5N NaOH (2 × 10 mL) and dried over sodium sulfate. Solvent was evaporated at reduced pressure and the residue was purified by flash chromatography on silica gel (dichloromethane:MeOH:2M ammonia in MeOH,
90:8:4) to give 0.905 g (90%) as a white powder. The HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether. The white powder was dried and recrystallized from anhydrous isopropanol. M.P. 233-235 °C; [α]D = +131.16 (c = 0.735,
MeOH); Anal. Calcd. for C30H34N5O5F2Cl : C, 58.30; H, 5.53; N, 11.06. Found: C, 57.91; H, 5.53; N, 11.10.
Example 5 (+)-trans-6-(3,4-Difluorophenyl) -1-{N- [2-(4-cyano-4-p h e n y l
cyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl- 4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride (Scheme 2; Step F).
A solution of (+)-5-methoxycarbonyl-4-methoxymethyl-1,2,3,6-tetrahydro-2-oxo-6-(3,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (0.850 g, 1.73 mmol) and trans-2-(4-cyano-4-phenyl-cyclohexylamino)
ethylamine (0.567 g, 2.42 mmol) in dichloromethane (30 mL) was stirred at room temperature for 12 hours. It was washed with ice-cold 0.5N NaOH (2 × 10 mL) and dried over sodium sulfate. Solvent was evaporated at reduced pressure and the residue was purified by flash chromatography on silica gel (dichloromethane:MeOH:2M ammonia in MeOH, 90:8:4) to give 0.905 g (90%) as a white powder. The HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether. Anal. Calcd. for C30H34N5O5F2Cl:C, 58.30; H, 5.53; N, 11.06. Found: C, 57.99; H, 5.73; N, 11.20.
Example 6
(-)-cis-6-(3,4-Difluorophenyl)-1-{N-[2-(4-cyano-4-p h e n y l
cyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl- 4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride. a) (-)-5-Methoxycarbonyl-4-methoxymathyl-1,6-dihydro-2- methoxy- 6 - ( 3 , 4 -dif luorophenyl ) - 1 - [ ( 4 - nitrophenyloxy)carbonyl]pyrimidine (Scheme 2; Step E) .
To a well stirred solution of (+)-5-methoxycarbonyl- 1, 6-dihydro-2-methoxy-4-methoxymethyl-6- (3,4- difluorophenyl)pyrimidine (1.167 g, 3.576 mmol) and 4- (N,N-dimethylamino)pyridine (0.655 g, 5.364 mmol) in
CH2C12 (20 mL) was added powdered 4-nitrophenyl chloroformate (0.937 g, 4.65 mmol) at room temperature. Solvent was evaporated ana the residue was purified by column chromatography on silica gel using hexanes/EtCAc
(7/3%) as the eluent to give (-)-5-methoxycarbonyi-4-methoxymethyl-1, 6-dihydro-2 -methoxy-6- (3 , 4 -diflurophenyl) -1-[(4-nitrophenyloxy)carbonyl]pyrimidine
(1.761 g, 100%) as a viscous oil. [α]D = -335.3 (c = 1.0 g in 100 mL CHCl3) . b) (-)-cis-6-(3,4-Difluorophenyl)-1-{N-[2-(4-cyano-4-phenylcyclohexylamino)ethyl]}carboxamido-5-methoxycarb o n y l - 4 - m e t h o x y m e t h y l - 2 - o x o -1,2,3,6-tetrahydropyrimidine hydrochloride (Scheme 2; G & Step F). A solution of (-)-5-methoxycarbonyl-4-methoxymethyl-1,6-dihydro-2-methoxy-6- (3,4-diflurophenyl)-1-[(4-nitrophenyloxy)
carbonyl]pyrimidine (0.103 g, 0.21 mmol) and cis-2-(4-cyano-4-phenyl-cyclohexylamino)ethylamine (0.059 g, 0.251 mmol) in dichloromethane (50 mL) was stirred at room temperature for 12 hours. It was washed with lcecold 0.5N NaOH (2 × 10 mL) and dried ever sodium sulfate. Solvent was evaporated at reduced pressure and the residue was purified by flash chromatography on silica gel (dichloromethane: MeOH:2M ammonia in MeOH, 90:8:4) to give 0.121 g (100%) as an oil. It was dissolved in THF (2 mL), treated with 0.2 mL of 6N HCl and stirred at room temperature for 4 h. Solvent was evaporated and the residue was dried in vacuo to give the product as a white powder (130 mg, 100%) . M.P. 220- 222 °C; [α]D = -124.29 (c = 0.535, MeOH); Anal. Calcd. for C30H34N5O5F2Cl : C, 58.30; H, 5.53; N, 11.06. Found: C, 57.20; H, 5.57; N, 11.30.
Example 7
(+)-trans-6- (3,4-Difluorophenyl) -1-{N- [2- (4-(2- pyridyl)-cyclohexylamino)ethyl]}carboxamido-5- methoxycarbonyl-4 -methoxymethyl- 2 -oxo - 1,2,3,6-tetrahydropyrimidine hydrochloride a) General procedure for 2-{4-arylcyclohexylamino]ethylamine (Scheme 2; Step A).
A mixture of 4-arylcyclohexanone (18.7 mmol) (i.e. 4- 2-pyridyl)-cyclohexanone) and ethylenediamine (3.73 g, 146 mmol) and p-toluenesulfonic acid (92 mg) in benzene (200 mL) was refluxed for 4 h in Dean-Stark trap to remove the water that formed. Solvent was evaporated and the residue was redissolved in methanol
(60 mL) and cooled to 0 ºC. To this, sodium borchydride (6.4 5 g) was added in portions and the mixture was stirred at room temperature for 3 h. Solvent was evaporated, the residue was dissolved in dichloromethane (300 mL), washed with brine (3 × 500 mL), dried (potassium carbonate., and the solvent evaporated to leave the product as a pale yellow viscous oil (90-95%). The product was pure and found to ccntain the cis/trans isomers. A careful chromatography of this mixture with chloroform/mechanol/2M ammonia in methanol (100/10/5 to 100/20/10 ) gave some earlier fractions enriched in the cis isomer. The fractions eluted at the end were almost pure trans isomer. b) (+)-trans-6-(3,4-Difluorophenyl)-1-{N-[2-(4-(2- p y r i d y l ) cyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl- 4-methoxymethyl-2-oxo-1,2,3,6-.etrahydro
pyrimidine hydrochloride (Scheme 2; Step G).
A solution of {+)-5-methoxycarbonyl-4-methoxymethyl- 1,2,3,6-tetrahydro-2-oxo-6-(3,4-difluorophenyl)-1-[(4- nitrophenyloxy)carbonyl]pyrimidine (49.1 mg, 0.1 mmol) and trans-2-(4-(2-pyridylcyclohsxylamino)ethylamine (30 mg, 0.136 mmol) in TΗF (10 mL) was stirred at room temperature for 12 hours. It was washed with ice-ccld 0.5N NaOH (2 × 5 mL) and dried over sodium sulfate.
Solvent was evaporated at reduced pressure and the residue was purified by preparative t1c on silica gel (ethyl acetate:MeOH, 10:1) to give 43 mg (78%) as a white powder. The HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether. 180-184 ºC; [α]D = +186 (c = 0.65, methanol); Anal. Calcd. for C28H35N5O5F2C12.0.4CH2Cl2 :C, 51.33; H,
5.43; N, 9.54. Found: C, 51.31; H, 5.43; N.9.69.
Examples 8 and 9
cis-6-(3,4-Difluorophenyl)-1-{N-[2-(4-phenylcyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl- 4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride
and
trans-6- (3,4-Difluorophenyl) -1-{N- [2- (4-phenylcyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydro pyrimidine hydrochloride a) 2-[4-Phenylcyclohexylimino]ethylamine (Scheme 5; Step A).
A mixture of 4-phenylcyclohexanone (4.00 g, 22.96 mmol) and ethylenediamine (1.66 g, 27.5 mmol) and p- toluenesulfonic acid (437 mg) in benzene (200 mL) was refluxed for 4 h in Dean-Stark trap to remove the water that formed. Tlc analysis indicated the completion of the reaction. Solvent was evaporated and the product was used in the next step without any further purification. b) cis-6-(3,4-Difluorophenyl)-1-{N- [2-(4- phenylcyclohexylamino)ethyl]}carboxamido-5-methoxycar bonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride
and
trans-6-(3,4-Difluorophenyl) -1-{N- [2-(4- phenylcyclohexylamino)ethyl]}carboxamido-5-methoxy carbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride (Scheme 5; Step B). A solution of 5-methoxycarbonyl-4-methyl-1,2,3,6-tetrahydro-2-oxo-6-(3,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (120 mg, 0.269 mmol) and 2-[4-phenyl-cyclohexylimino]ethylamine (69.3 mg, 0.33 mmol) in dichloromethane (20 mL) was stirred at room temperature for 12 hours. Solvent was evaporated, the residue was redissolved in ethanol (10 mL) and cooled to 0 °C. To this sodium borohydride (61 mg, 1.614 mmol) was added and the stirring continued for 2 h. Solvent was evaporated and the residue was purified by preparative tic on silica gel using (dichloromethane:MeOH:2M ammonia in MeOH, 100:8:4) as eluent. Two products were isolated, the upper band corresponds to cis-6-(3,4-Difluorophenyl)-1-{N-[2-(4-phenyl-cyclohexylamino)ethyl]}carboxyamido-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (16 mg), and the lower band to trans-6-(3,4-Difluorophenyl)-1-(N-[2-(4-phenylcyclohexylamino)ethyl]}carboxamido-5-methoxycar bonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (42 mg). The HCl salts were prepared by treatment of a solution of the free base in ether with 1N HCl in ether. Example 8: The cis isomer: M.P 145-146 °C; Anal. Calcd. for C28H33N4O4F2Cl 0.8H2O:C, 58.24; H, 6.04; N, 9.70. Found: C, 58.13; H, 5.83; N, 9.50.
Example 9: The trans isomer: M.P 156-157 °C; Anal. Calcd. for C28H33N4O4F2Cl 0.4CHCl3:C, 55.85; H, 5.51; N, 9.17. Found: C, 55.57; H, 5.76; N, 9.10.
Example 10
trans-6- (3, 4-Difluorophenyl) -1-{N- [2 - [ (4- p h e n y l c y c l o h e x y l ) - m e t h y l - amino]ethyl]}carboxamido-5-methoxycarbonyl-4-methyl-2- oxo-1,2,3,6-tetrahydropyrimidine hydrochloride (Scheme 5; Step C).
A mixture of trans-6-(3,4-difluorophenyl)-1-{N-[2-(4-p h e n y l cyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine (60 mg, 0.114 mmol), methyl iodide (19.4 mg, 0.137 mmol, 1.2 eq.), and potassium carbonate (31.5 mg, 0.23 mmol) in acetone (10 mL) was stirred and refluxed for 12 h and the solid was removed by filtration. Solvent was evaporated from the filtrate and the residue was purified by flash chromatography on silica gel (dichloromethane: MeOH:2M ammonia in MeOH, 90:8:4) to give the product as an oil. The HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether (14 mg). M.P. 140-142 °C, Anal Calcd. for C29H35N4O4F2Cl.0.33hexanes.0.59CHCl3:C, 56.07, H, 5.99; N, 8.28. Found: C, 56.37; H, 6.21; N, 7 90.
Example 11
(+) -cis-6- (3,4-Difluorophenyl) -1-{N- [2- ( 4 - m e t h o x y c a rb o n y l - 4 - p h e n y l cyclohexylamino)ethyl]}carbox
amido-5-methoxycarbonyl-4-methoxymethyl-2-oxo- 1,2,3,6-tetrahydropyrimidine hydrochloride a) 2 - [4 -Methoxycarbonyi - 4 -phenyl cyclohexylamino]ethylamine (Scheme 2; Step B).
A m i x t u r e o f 2 - [ 4 - c y a n o - 4 - phenylcyclohexylamino]ethylamine (2.34 g, 10 mmol) and concentrated sulfuric acid (20 mL) was heated at 80-85 °C for 10 h. It was cooled to room temperature, mixed with anhydrous methanol (200 mL), and refluxed for 20 h. Solvent was evaporated and the residue was poured onto ice (200 g) and basified to pH 11 by addition 6N NaOH. It was extracted with dichloromethane (4 × 125 mL), dried (potassium carbonate) and solvent evaporated to leave the product as an oil (2.1 g, 76%). This prcαuct was a pure mixture of ci s ana trans isomers. It was used in the next step witnout any furtner purification. b) (+) - c i s-6-(3,4-Difluorophenyl) -1-{N-[2- (4-methoxycarbonyl-4-phenyl-cyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride (Scheme 2; Step G).
A solution of (+)-5-methoxycarbonyl-4-methoxymethyl-1,2,3,6-tetrahydro-2-oxo-6-(3,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (128 mg, 0.26 mmol) and 2- (4-methoxcarbonyl-4-phenylcyclohexylamino)ethylamine (70 mg, 0.26 mmol) in dichloromethane (15 mL) was stirred at room temperature for 12 hours. It was washed with ice-cold 0.5N NaOH (2 × 5 mL) and dried over sodium sulfate. Solvent was evaporated at reduced pressure and the residue was purified by flash chromatography on silica gel (dichloromethane:MeOH:2M ammonia in MeOH, 90:8:4) to give 78 mg (781) as a white powder. The HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether. 112-114 °C; [α]D = +136 (c = 0.55, CHCl3) ; Anal. Calcd. for C31H37N4O7F2C1.0.4CH2Cl2 :C, 55.05; H, 5.56; N, 8.18. Found: C, 55.05; H, 5.50; N, 8.16.
Example 12
(+)-6-(3,4-Difluorophenyl)-1-{N-[2-(4,4-diphenylcyclohexylamino)ethyl]}carboxamido-5-methoxycarbonyl- 4-methoxymethyl-2-oxo-1,2,3,6-tetrahydro
pyrimidine hydrochloride a) 2-[4,4-Diphenylcyclohexylamino]ethylamine (Scheme 2; Step A) .
A mixture of 4,4-diphenylcyclohexanone (2.5 g) and ethylenediamine (10 g) and p-toluenesulfonic acid (100 mg) in benzene (200 mL) was refluxed for 4 h in Dean- Stark trap to remove the water that formed. Solvent was evaporated and the residue was redissolved in methanol (60 mL) and cooled to 0 °C. To this, sodium borohydride (2 g) was added in portions and the mixture was stirred at room temperature for 3 h. Solvent was evaporated, the residue was dissolved in dichloromethane (300 mL), washed with brine (3 × 500 mL) , dried (potassium carbonate), and the solvent evaporated to leave the product as a colorless viscous oil (2.94 g, 100%). The 1H-NMR showed this product to be pure and was used in the next step without any further purification. b) (+)-6-(3,4-Difluorophenyl)-1-{N-[2-(4,4-diphenylcyclohexylamino)ethyl]}carboxamido-5-methoxyc arbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydro pyrimidine hydrochloride (Scheme 2; Step G).
A solution of (+)-5-methoxycarbonyl-4-methoxymethyl- 1,2,3,6-tetrahydro-2-oxo-6-(3,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (125 mg, 0.254 mmol) and 2- (4, 4-diphenylcyclohexylamino) ethylamine (125 mg, 0.446 mmol) in THF (15 mL) was stirred at room temperature for 12 hours. It was washed with ice-cold 0.5N NaOH (2 × 5 mL) and dried over sodium sulfate. Solvent was evaporated at reduced pressure and the residue was purified by flash chromatography on silica gel (dichloromethane:MeOH:2M ammonia in MeOH, 90:8:4) to give 147 mg (92%) of the product as a white powder. The HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether. 160-162 °C; [α]D = +184 (c = 0.68, methanol); Anal. Calcd. for C35H39N4O5F2Cl.0.19CH2Cl2 :C, 61.68; H, 5.79; N, 8.18. Found: C, 62.82; H, 5.87; N, 8.37. Example 13
(+)-cis-6-(3,4-Difluorophenyl)-1-{H-[2-(4-cyano-4-(2- fluorophenyl)-cyclohexylamino)ethyl]}carboxamido-5- methoxycarbonyl-4-methyl-2-oxo-1, 2, 3 , 6-tetrahydropyrimidine hydrochloride (Scheme 2; Step G).
A mixture of (+)-6-(3,4-difluorophenyl)-1,6-dihydro-5-methoxycarbonyl-4-methyl-1-(4-nitro)phenoxycarbonyl-2-cyrimidone (60 mg, 0.138 mmol), cis-2-[4-cyanc-4-(2-fluorophenyl)cyclohexylamino]ethylamine (50 mg, 0.15 mmol) and methylene chloride (4 mL) was stirred at room temperature overnight. After being washed with 1N ΝaOH solution, the organic layer was concentrated and purified by preparative TLC (eluent: 10/1 ethyl acetate/2M ammonia in methanol) to give the title compound in 41% yield (32 mg) as a yellow foam: DCIMS, m/z = 570 (MH+) . Treatment of the free base with 1 equivalent of 1M HCl in ether gave the HCl salt as an off-white solid: m.p. 172-176°C. [α]D= 114.7 (1.9 mg/mL MeOH). Anal. Calc . for C2,H30F3Ν5O4 HCl 0.5CHCl3 : C, 53.22; H, 4.77; N, 10.52. Found: C, 53.34; H, 4.77; N, 10.45. Example 14
(+)-cis-6-(3,4-Difluorophenyl)-1-{N-[2-(4-cyano-4-(2- pyridyl)-cyclohexylamino)ethyl]}carboxamido-5- methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6- tetrahydropyrimidine hydrochloride (Scheme 2; Step G) .
A mixture of (+)-6-(3,4-difluorophenyl)-1,6-dihydro-5- methoxycarbonyl-4-methoxymethyl-1-(4-nitro)phenoxy carbonyl-2-pyrimidone (50 mg, 0.107 mmol), cis-2-[4- cyano-4-(2-pyridyl)cyclohexylamino]ethylamine (40 mg, 0.164 mmol) and methylene chloride (4 mL) was stirred at room temperature overnight. After being washed with IN ΝaOH solution, the organic layer was concentrated and purified by preparative TLC (eluent: 10/1 ethyl acetate/2M ammonia in methanol) to give the title compound in 50% yield (31 mg) as a yellow oil: CIMS, m/z = 583 (MH+) . Treatment of the free base with 2 equivalents of 1M HCl in ether gave the HCl salt as an cff-whlte solid: m.p. 148-152ºC. [α]D = 110.9 (1.65 mg/mL MeOH). Anal. Calc. for C29H32F2N6O52HCl 0.65CHCl3 : C, 48.58; H, 4.76; N, 11.46. Found: C, 48.30; H, 4.87; N, 11.20.
Example 15
cis-6-(3,4-Difluorophenyl)-1-{N-[3-(4-cyano-4-phenylcyclohexylamino)propyl]}carboxamido-5-methoxycarbonyl-4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride a) General procedure for 3-[4-Cyano-4-arylcyclohexylamino]propylamine. a) 3-[4-Cyano-4-phenylcyclohexylamino]propylamine
(Scheme 6; Step A).
A mixture of 4-cyano-4-phenylcyclohexanone (5.0 g, 25.09 mmol) and 1,3-diaminopropane (5.58 g, 75.3 mmol) and p-toluenesulfonic acid (23 mg) in benzene (50 mL) was refluxed for 4 h in Dean-Stark trap to remove the water that formed. Solvent was evaporated and the residue was redissolved in methanol (40 mL) and cooled to 0 °C. To this, sodium borohydride (6.4 5 g) was added in portions and the mixture was stirred at room temperature for 3 h. Solvent was evaporated, the residue was dissolved in dichloromethane (300 mL), washed with brine (3 × 500 mL), dried (potassium carbonate), and the solvent evaporated to leave the product as a pale yellow viscous oil (4.5 g, 72%). The 1H-NMR showed this product to be pure and found to contain the cis/trans isomers in the ratio of about 4 :1. b) cis-6-(3,4-Difluorophenyl)-1-{N-[3-(4-cyano-4- p h e n y l
cyclohexylamino)propyl]}carboxamido-5-methoxycarbonyl -4-methyl-2-oxo-1,2,3,6-tetrahydropyrimidine hydrochloride (Scheme 6; Step B).
A solution of 5-methoxycarbonyl-4-methyl-1,2,3,6-tetrahydro-2-oxo-6-(3,4-difluorophenyl)-1- ((4-nitrophenyloxy)carbonyl]pyrimidine (0.500 g, 1.15 mmol) and 3-[4-cyano-4-phenylcyclohexylarrtino]propylamine
(0.371 g, 1.49 mmol) in dichloromethane (50 mL) was stirred at room temperature for 12 hours. It was washed with ice-cold 0.5N NaOH (2 × 10 mL) and dried over sodium sulfate. Solvent was evaporated at reduced pressure and the residue was purified by flash chromatography on silica gel (dichloromethane:MeOH:2M ammonia in MeOH, 90:8:4) to give 0.570 g (87.6%) of the product as a white powder. The HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether. M.p. 163-165 °C; Anal. Calcd. for
C30H34N5O4F2Cl.1.2 H2O:C, 57.77; H, 5.88; N, 11.23. Found: C, 57.65; H, 5.71; N, 11.20.
Example 16
(+)-cis-1-3-{[4-(3,4-Difluorophenyl)-2,5-dioxo- 1,2,3,4,5,7-hexahydro-4H-furo[3,4-d]-pyrimidine-3- carbonyl]amino}-ethyl-(4-cyano-4-phenylcyclohexyl)amine hydrochloride. a) (+)-6-(3,4-Difluorophenyl)-1,6-dihydro-2-oxo-5- methoxy-carbonyl-4-bromomethyl-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (Scheme 7; Step A).
To a well stirred solution of (+)-6-(3,4- difluorophenyl) -1, 6-dihydro-2-methoxy-5- methoxycarbonyl-4-methyl-1-[(4-nitrophenyloxy) carbonyl]pyrimidine (1.5 mmol, 0.66 g) in 5 mL of chloroform was added a solution of bromine (1.5 mmol, 0.09 mL) in 3 mL of chloroform at 0°C and the solution was allowed to attain room temperature over 1.5 h. The solvent was removed in vacuo and the residue was again dissolved in CHCl3 (20 mL) and washed with brine. The organic layer was separated, dried over Na2SO4, filtered and the solvent was removed in vacuo to get 0.81 g of (+) -6- (3,4-difluorophenyl)-1,6-dihydro-2-oxo-5-methoxycarbonyl-4-bromomethyl-1-[(4-nitrophenyloxy)carbonyl]pyrimidine as a yellow foam. It was used in tne next step without any purification. b) (+)-4-(3,4-Difluorophenyl)-2,5-dioxo-1,2,4,5,6,7-hexahydro-cyclopentapyrimidine-3-carboxylic acid-4-nitrophenyl ester (Scheme 7; Step B).
(+)-6-(3,4-Difluorophenyl)-1,6-dihydro-2-oxo-5-methoxycarbonyl-4-bromomethyl-1-[(4-nitrophenyloxy)carbcnyl]pyrimidine (1.5 mmol, 0.81 g) was heated in oil bath for 3 h (bath temperature 130°C. The brown residue thus obtained was washed with CHCl3 and (+)-4-(3,4-difluorophenyl) -2, 5-dioxo-1, 2, 4, 5,6, 7-hexahydrocyclopentapyrimidine-3-carboxylic acid-4-nitrophenyl ester was obtained as a pale brown solid which was used in the next step without further purification (crude wt. 0.51g). c) (+)-cis-1-3-{[4-(3,4-Difluorophenyl)-2,5-dioxo- 1,2,3,4,5,7-hexahydro-4H-furo[3,4-d]-pyrimidine-3- carbonyl]amino}-ethyl-(4-cyano-4-phenylcyclohexyl) amine hydrochloride (Scheme 7; Step C).
A solution of (+)-4-(3,4-difluorophenyl)-2,5-dioxo- 1,2,4,5,6,7-hexahydro-cyclopenta pyrimidine-3- carboxylic acid-4-nitrophenyl ester (86 mg, 0.20 mmol) and cis-2-(4-cyano-4-phenylcyclohexylamino)ethyl amine (70 mg, 0.3 mmol) in THF (5 mL) was stirred at room temperature for 12 hours. It was purified by preparative tic on silica gel (ethyl acetate/methanol, 90:10) to give 91 mg (85%) as a white powder. The HCl salt was prepared by treatment of a solution of the free base in ether with 1N HCl in ether. [α]D = +102 (c = 0.75, MeOH); Anal. Calcd. for C28H27N5O4F2Cl .0.38CH2Cl2; C, 56.41; H, 4.80; N, 11.59. Found: C, 56.80; H, 4.96; N, 11.29. Example 17
(+)-cis - 6 -(3,4-Difluorophenyl)-1-[4-(4-cyano-4-phenylcyclohexylamino)butyl]-5-methoxycarbonyl-2,4-dimethyl- 1,6-dihydropyrimidine hydrochloride (Scheme 8).
To a suspension of NaH (50 mg, 60% dispersion in mineral oil) in THF (7 mL) was added a solution of 6- (3,4-difluorophenyl)-1,6-dihydro-5-methoxycarbonyl-2, 4-dimethylpyrimidine (0.32 g, 1.14 mmol.) and HMPA
(0.205g, 1.14 mmol.) in THF (8 mL) at 0°C. After 15 min, 1,4-dibromobutane (0.47 mL, 4.0 mmol.) was added. The reaction mixture was then refluxed for 10 min. The solid was filtered off. After the removal of the solvent, the residue was flash chromatographed over silica gel (eluent: ethyl acetate) to give the product in 44% yield (0.2 g) as a yellow oil.
A mixture of 1-(4-bromobutyl)-6-(3,4-difluorophenyl)- 1,6-dihydro-5-methoxycarbonyl-2,4-dimethylpyrimidine (0.1 g, 0.43 mmol), cis-4-cyano-4-phenylcyclohexylamine (0.18 g, 0.9 mmol), potassium carbonate (0.3 g, 2.1 mmol), sodium iodide (65 mg, 0.43 mmol) and acetone (6 mL) was refluxed overnight. After removal of the solid and solvent, the residue was purified by preparative TLC (eluent: 100/20 v/v ethyl acetate-2M ammonia in methanol) to give the product in quantitative yield (0.23 g) as a pair of diastereomers. HPLC separation (Column: Chiralcel OD 20x250 mm; Eluent: 60/40/0.1 hexane/2-propanol/diethylamine) gave the pure title compound as a yellow oil: DCIMS, m/z = 535 (MH+). Treatment of the free base with 2 equivalents of 1M HCl in ether gave the HCl salt as a white solid: m.p. 169- 172°C. [α]D - 68.6 (2.2 mg/mL MeOH). Anal. Calc. for C31H36F2N4O2·2C1 0.9CHCl3: C, 53.59; H, 5.48; N, 7.84. Found: C, 53.61; H, 5.67; N, 7.81.
It is understood that additional compounds may be synthesized under the general synthetic schemes referred to herein using appropriately substituted starting materials.
Example 18
(+)-6-(3,4-Difluorophenyl)-1-{N-[2-(4-cyano-4-phenylcyclohex-1-ylamino)-ethyl]}carboxamido-5-methoxycarbonyl-4-hydroxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine.
To well-stirred solution of ( +)-6-(3,4-difluorophenyl)-1-{N-[2- (4-cyano-4-phenylcyclohex-1-ylamino)-ethyl]}carboxamido-5-methoxycarbonyl-4-methoxymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (0.108 g, 0.184 mmol) in
dichloromethane (8 mL) at -78°C was added a 1M solution of boron tribromide (0.55 mL) dropwise and the cooling bath was removed. After stirring the mixture at room temperature for 4 h, it was quenched by the addition of methanol (5 mL). Solvent was
evaporated and the residue was purified by preparative thinlayer chromatography on silica gel using chloroform/methanol/2M ammonia in methanol (95/4/1) as the eluent. The faster moving component (Rf = 0.6, TLC on silica gel plates eluting with 25:2:1
CHCl3:CH3OH: 2M NH3 in CH3OH) corresponded to
(+)-6-(3,4-difluorophenyl)-1-{N-[2-(4-cyano-4-phenylcyclohex-1-ylamino)-ethyl]}carboxamido-5-methoxycarbonyl-4-bromomethyl-2-oxo-1,2,3,6-tetrahydropyrimidine and it was
converted to the hydrochloride salt by treatment with 1N HCl in ether (10 mg); MH+ = 630; M.P. 225-227 °C; [α]D = +126 (c =
0.115, MeOH); Anal. Calcd. for C29H31N5O4F2Cl .0.2CH2Cl2 : C, 51.28; H, 4.63; N, 10.24. Found: C, 51.40; H; 4.58; N, 10.12. A second component (Rf = 0.5, TLC on silica gel plates eluting with 25:2:1 CHCl3: CH3OH: 2M NH3 in CH3OH) was identified as
(+)-6-(3,4-difluorophenyl)-1-{N-[2-(4-cyano-4-phenylcyclohex-1-ylamino)-ethyl]}carboxamido-5-methoxycarbonyl-4-hydrox ymethyl-2-oxo-1,2,3,6-tetrahydropyrimidine (45 mg); MH+ = 568; M.P. 230-232 °C; [α ]D = +123 (c = 0.275, MeOH); Anal. Calcd. for C29H31N5O5F2.0.35CH2Cl2: C, 59.02; H, 5.35; N, 11.72. Found: C, 58.93; H; 5.50; N, 11.68. Example 19
(+)-6-(3,4-Difluorophenyl)-1-{N-[2-(4-cyano-4-phenylcyclohex-1-ylamino)-ethyl]}carboxamido-4-methoxymethyl-2-oxo 1,2,3,6-tetrahydropyrimidine-5-carboxylic acid. a) Benzyl 2-[(3,4-difluorophenyl)methylene]-3-oxo-4-methoxybutyrate. To a solution of benzyl 4-methoxyacetoacetate
(84 g, 0.37 mol), 3,4-difluorobenzaldehyde (52.5 g, 0.0.37 mmol), and piperidinium acetate (1.58 g, 2.63 mmol) in benzene (1L) were added molecular sieves (400 g) and the mixture was stirred at room temperature for 48 h. The molecular sieves were removed by filtration and the solvent was evaporated from the filtrate under reduced pressure. The residue was purified by column
chromatography on silica gel using chloroform/ethyl acetate
(100:3) to get the product as a white powder (118 g, 91%). The NMR showed this product to be a mixture of cis and trans lsomers. b) 5-Benzyloxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine. A suspension of benzyl 2-[(3,4-difluorophenyl)methylene]-3-oxo-4-methoxybutyrate (60 g, 0.181 mol), O-methylisourea hemisulfate (46.77 g, 0.271 mol, 1.5 eq.), and sodium bicarbonate (53.25 g, 0.634 mol, 3.5 eq.) in ethanol
(400 mL) was stirred at 50-55°C for 6 h. The solvent was
evaporated from the combined filtrates and the residue was purified by column chromatography (SiO2, EtOAc/hexane, 10%-30%) to give 5-benzyloxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine as a pale yellow oil (24.7 g, 35%). c) 5-Benzyloxycarbonyl-4-methoxymethyl-1,6-dihydro-2-methoxy-6- (3,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine.
To a well-stirred solution of 5-benzyloxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine (12 g, 29 mmol) and pyridine (10 mL) in CH2Cl2 (100 mL) was added
powdered 4-nitrophenyl chloroformate (8.69 g, 43 mmol) at 0°C. The reaction mixture was stirred for 12 h at room temperature and the solvent was evaporated from the filtrate and the residue was purified by column chromatography (SiO2, dichloromethane/hexane, 20%-50%) to give the product as a foam (14.2 g, 86%). d) (+)-5-Benzyloxycarbonyl-4-methoxymethyl-1,6-dihydro-1-{N-[2-phenyl)ethyl]}carboxamido-2-methoxy-6-(3,4-difluorophenyl)pyrimidine. To a stirred solution of 5-benzyloxycarbonyl-4-methoxymethyl-1,6-dihydro-2-methoxy-6-(3,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (6 g, 10.5 mmol) in THF (120 mL) was added R- (+)-α-methylbenzylamine (1.8 g, 15 mmol) at room temperature and the stirring was
continued for 12 h. Solvent was evaporated and the residue was purified by column chromatography (SiO2, 10-20% EtOAc in hexane). The first major product to elute was (+)-5-benzyloxycarbonyl-4-methoxmethyl-1,6-dihydro-1-{N-[2-phenyl)ethyl]}carboxamido-2-methoxy-6-(3,4-difluorophenyl)pyrimidine (2.1), as an oil. e) (+)-5-Benzyloxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine. To a stirred solution of (+)-5-benzyloxycarbonyl-4-methoxymethyl-1,6-dihydro-1-{N-[2-phenyl)ethyl]}carboxamido-2-methoxy-6-(3,4-difluorophenyl)pyrimidine (2 g, 3.5 mmol) in dichloromethane (200 mL) was added 1,8-diazabicyclo[5,4,0]-undec-7-ene (0.6 mL) and the mixture was stirred at room temperature for 12 h. Solvent was evaporated and the residue was purified by flash column
chromatography on silica gel with 30-40% EtOAc in hexane as eluent to give (+)-5-benzyloxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4-difluorophenyl)pyrimidine as a viscous oil (1.25 g, 86%). f) (+)-5-Benzyloxycarbonyl-4-methoxymethyl-1,6-dihydro-2-methoxy-6-(3,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine.
To a well stirred solution of (+)-5-benzyloxycarbonyl-1,6-dihydro-2-methoxy-4-methoxymethyl-6-(3,4- difluorophenyl)pyrimidine (1.25 g, 3.0 mmol) and pyridine (2 mL) in CH2Cl2 (20 mL) was added powdered 4-nitrophenyl chloroformate (1 g, 5 mmol) at room temperature. Solvent was evaporated and the residue was purified by column chromatography on silica gel using CHCl3/EtOAc (20%-50%) as the eluent to give (+)-5-benzyloxycarbonyl-4-methoxymethyl-1,6-dihydro-2-methoxy-6-(3,4-diflurophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (1.70 g, 86%) as a viscous oil. [α]D = +200 (c = 1.215 g in 100 mL CHCl3) . g) (+)-6-(3,4-Difluorophenyl)-1-{N-[2-(4-cyano-4-phenylcyclohex-1-ylamino)-ethyl]}carboxamido-5-benzyloxycarbonyl-4-methoxymethyl-2-oxo 1,2,3,6-tetrahydropyrimidine (cis isomer).
A solution of (+)-6-(3,4-difluorophenyl)-1,6-dihydro-2-methoxy-5-benzyloxycarbonyl-4-methoxymethyl-1-(4-nitrophenoxy)-carbonylpyrimidine (0.100 g) and 2-[4-cyano-4-phenylcyclohex-1-yl]aminoethylamine (0.05 g) in THF (5 mL) was stirred at room temperature for 12 hours. To this 6N HCl (0.5 ml) was added and the stirring was continued for 2 h. Solvent was evaporated, the residue was mixed with dichloromethane (10 mL), washed with ice-cold 0.5N NaOH (2 × 10 mL) and dried over sodium sulfate.
Solvent was evaporated at reduced pressure and the residue was purified by flash chromatography on silica gel
(dichloromethane:MeOH:2M ammonia in MeOH, 90:8:4) to give 0.12 g of the product as a white powder. The NMR showed this product to be pure and was used in the next step without any further
characterization. h) (+)-6-(3,4-Difluorophenyl)-1-{N-[2-(4-cyano-4-phenylcyclohex-1-ylamino)-ethyl]}carboxamido-4-methoxymethyl-2-oxo 1,2,3,6-tetrahydropyrimidine-5-carboxylic acid.
To a solution of (+)-6-(3,4-difluorophenyl)-1-{N-[2-(4-cyano-4-phenylcyclohex-1-ylamino)-ethyl]}carboxamido-5-benzyloxycarbonyl-4-methoxymethyl-2-oxo 1,2,3,6-tetrahydropyrimidine (120 mg) in methanol/water (9/1, 10 mL), 10% palladium on charcoal (20 mg) was added and the mixture was hydrogenated at 125 psi for 4 h. The t1c analysis of the reaction indicated the completion of the reaction. The catalyst was removed by filtration and the solvent was evaporated to leave the product as a pale yellow powder (86 mg); m.p 188-191°C; Anal. Calcd. for C29H31N5O5F2 0.5H2O : C, 60.41; H, 5.59; N, 12.15. Found: C, 60.28; H; 5.62; N, 12.34.
Example 20
As a specific embodiment of an oral composition cf a compound of this invention, 100 mg of one of tr.e compounds described herein is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.
Pharmacological Profiles of the Compounds in Cloned Human Adrenergic Receotors.
Binding affinities were measured for selected compounds of the invention at six cloned human alpha-1 and alpha- 2 receptor subtypes, as well as at the L-type calcium channel. The protocols for these experiments are given below.
Protocol for the Determination of the Potency of α1 Antagonists
The activity of compounds at the different human receptors was determined in vitro using cultured cell lines that selectively express the receptor of interest. These cell lines were prepared by transfecting the cloned cDNA or cloned genomic DNA or constructs containing both genomic DNA and cDNA encoding the human αt-adrenergic receptors as follows: α1D Human λdrenergic Receptor: The entire coding region of α1D (1719 bp), including 150 base pairs of 5' untranslated sequence (5' UT) and 300 bp of 3' untranslated sequence (3' UT), was cloned into the BamHI and ClaI sites of the polylinker-modified eukaryotic expression vector pCEXV-3, called EXJ.HR. The construct involved the ligation of partial overlapping human lymphocyte genomic and hippocampal cDNA clones: 5' sequence were contained on a 1.2 kb SmaI-XhoI genomic fragment (the vector-derived BamHI site was used for subcloning instead of the internal insert-derived Smal site) and 3' sequences were contained on an 1.3 kb XhoI-ClaI cDNA fragment (the Clal site was from the vector polylinker). Stable cell lines were obtained by cotransfection with the plasmid α1A/EXJ (expression vector containing the α1A receptor gene (old nomenclature)) and the plasmid pGCcos3neo (plasmid containing the aminoglycoside transferase gene) into LM(tk-) cells using calcium phosphate technique. The cells were grown, in a controlled environment (37°C., 5% CO2), as monolayers in Dulbecco's modified Eagle's Medium (GIBCO, Grand Island, NY) containing 25mM glucose and supplemented with 10% bovine calf serum, 100 units/ml penicillin g, and 100 μg/ml streptomycin sulfate. Stable clones were then selected for resistance to the antibiotic G-418 (1 mg/ml), and membranes were harvested and assayed for their ability to bind [3H]prazosin as described below (see "Radioligand Binding assays"). The cell line expressing the human α1D receptor used herein was designated L-α1A (old nomenclature) and was deposited with the American Type Culture Collection, 12301 Parklavm Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. The cell line expressing the human α10 receptor, was accorded ATCC Accession No. CRL 11138, and was deposited on September 25, 1992. α1B Human Adrenergic Receptor: The entire coding region of α1B (1563 bp), including 200 base pairs and 5' untransiated sequence (5' UT) ana 600 bp cf 3' untranslated sequence (3' UT), was cloned into tne EcoRI site of pCEXV-3 eukaryotic expression vector The construct involved ligating the full-length containing EcoRI brainstem cDNA fragment from λ ZapII into the expression vector. Stable cell lines were selected as described above. The cell line used herein was designated L-α1B and was deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20832, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. The cell line L-α1B was accorded ATCC Accession No. CR 11139, on September 29, 1992. α1AHuman λdrenergic Receptor: The entire coding region of α1A (1401 bp), including 400 base pairs of 5' untranslated sequence (5' UT) and 200 bp of 3' untranslated sequence (3' UT), was cloned into the Kpnl site of the polylinker-modified pCEXV-3-derived eukaryotic expression vector, EXJ.RH. The construct involved ligating three partial overlapping fragments: a 5' 0.6kb Hindi genomic clone, a central 1.8 EcoRI hippocampal cDNA clone, and a 3' 0.6Kb PstI genomic clone. The hippocampal cDNA fragment overlaps with the 5' and 3' genomic clones so that the Hindi and Pstl sites at the 5' and 3' ends of the cDNA clone, respectively, were utilized for ligation. This full- length clone was cloned into the Kpnl site of the expression vector, using the 5' and 3' Kpnl sites of the fragment, derived from vector (i.e., pBluescript) and 3'-untranslated sequences, respectively. Stable cell lines were selected as described above. The stable cell line expressing the human α1A receptor used herein was designated L-α1C (old nomenclature) and was deposited with the American Type Culture Collection, 12301 Parkiawn Drive, Rockvilie, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for tne International Recognition of the Deposit of Microorganisms for the Purposes of Patent Proceαure The cell line expressing the human α1A receptor was accorded Accession No. CR 11140, on September 25, 1992.
Radioligand Binding Assays: Transfected cells from culture flasks were scraped into 5ml of 5mM Tris-HCl, 5mM EDTA, pH 7.5, and lysed by soincation. The cell lysates were centrifuged at 1000 rpm for 5 min at 4°C, and the supernatant was centrifuged at 30,000 x g for 20 min at 4°C. The pellet was suspended in 50mM Tris-HCl, 1mM MgCl2, and 0.1% ascorbic acid at pH 7.5. Binding of the α1 antagonist [3H]prazosιn (0.5 nM, specific activity 76.2 Ci/mmol) to membrane preparations of LM(tk-) cells was done in a final volume of 0.25 ml and incubated at 37°C for 20 min. Nonspecific binding was determined in the presence of 10 μM phentolamine. The reaction was stopped by filtration through GF/B filters using a cell harvester. Inhibition experiments, routinely consisting of 7 concentrations of the tested compounds, were analyzed using a non-linear regression curve-fitting computer program to obtain Ki values. or, Human Adrenergic Receptors: To determine the potency of α1 antagonists at the α2 receptors, LM(tk-) cell lines stably transfected with the genes encoding the α2A, α2B, and a2C receptors were used. The cell line expressing the α2A receptor is designated L-α2A, and was deposited on November 6, 1992 under ATCC Accession No. CRL 11180. The cell line expressing the α2B receptor is designated L-NGC-α2B, and was deposited on October 25, 1989 under ATCC Accession No. CRL10275. The cell line expressing the α2C receptor is designated L-α2C, and was deposited on November 6, 1992 under ATCC Accession No. CRL-11181. Ail the cell lines were deposited with the
American Type Culture Collection, 12301 Parklawn Drive,
Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the
Purposes of Patent Procedure. Cell lysates were prepared as described above (see Radioligand Binding
Assays), and suspended in 25mM glycylglycine buffer (pH
7.6 at room temperature). Equilibrium competition binding assay were performed using [3H] rauwoiscine
(0.5nM), and nonspecific binding was determined by incubation with 10μM phentolamine. The bound radioligand was separated by filtration through GF/B filters using a cell harvester.
Determination of the Activity of or. Antagonists at Calcium Channels
The potency of α1 antagonists at calcium channels was determined in competition binding assays of [1H]nitrendipine to membrane fragments of rat cardiac muscle, essentially as described by Glossman and Ferry
(Methods in Enzymology 109:513-550, 1985). Briefly, the tissue was minced and homogenized in 50mM Tris-HCl
(pH 7.4) containing 0.1mM pheyylmethylsulfonyl fluoride. The homogenates were centrifuged at 1000 g for 15 minutes, the resulting supernatant was centrifuged at 45,000 g for 15 minutes. The 45,000 g pellet was suspended in buffer and centrifuged a second time. Aliquots of membrane protein were incubated for 30 minutes at 37°C in the presence of [3H]nitrendipine
(1nM), and nonspecific binding was determined in the presence of 10μM nifedipine. The bound radioligand was separated by filtration through GF/B filters using a cell harvester.
The compounds described above were assayed using cloned human alpha adrenergic receptors and the rat calcium channel. The preferred compounds were found to be α1A selective antagonists. The compounds described herein were also found to exhibit weak binding affinity to the rat L-type calcium channel. The alpha adrenergic receptor binding affinities of compounds 2-5, 7, 11, 13 and 14 are illustrated in Table 1 as follows:
Figure imgf000068_0001
Figure imgf000069_0001
In Part 1 of the general syntnetic scheme, an
optionally substituted cycloalkanone is refluxed with a diaminoalkane to form the corresponding (cycloalk-1-yl)aminoalkylimine, which on treatment with Na3O. yields (cycloalk-1-yl) aminoalkylamine. In part 3 the diamine is added to a 1-[(4-nitrophenyl)oxycarbonyl]pyrimidine to yield the final product. Although cyclohexanone is shown, the process is equally applicable to substituted cycloalkanones from cyclobutanone through cyclooctanone. In addition, replacement of the diaminoalkane of Part 1 with an aminoalkanol yields esters in Part 3 instead of amides. In the schemes which fellow, the diaminoalkane is shown for clarity as either ethyl, propyl or butyl; however, any suitable alkyl, branched alkyl or substituted alkyl as shown in Scheme 1 may be used, wherein R is as defined in the specification.
In Part 2 of the general synthetic scheme, it is important to note that the use of the O-methylisourea (R"" = OMe) in Step D allows the production of several different 2-substituents on the dihydropyrimidine. In particular, addition of primary amines (i.e., NH2R3) to the 2-methoxy pyrimidines affords 2-amino pyrimidines. Alternatively, when R"" = OMe is replaced with 4- methoxybenzylthiol, 2-thioxodihydropyrimidines may be produced by treatment of the product with ethanethiol and TFA.
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Similar compounds may be produced by substitution of the 1,4-dibromobutane with other dibromoalkanes, including branched compounds in order to produce the alkyl-linked cycloalkylamine derivatives of the subject dihydropyrimidines.

Claims

What is claimed is:
1. A compound having the structure:
Figure imgf000081_0001
-
Figure imgf000081_0002
Figure imgf000082_0002
Figure imgf000082_0001
or
Figure imgf000083_0001
where M has the structure
Figure imgf000083_0002
wherein each of Y1, Y2, Y3, Y4 and Y5 independently may be -H; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monof luorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I;
-NO2; -N(R3)2; -N3; -CN; -OR3 -OCOR3; -COR3; -CON(R3)2; or -CO2R3; or wherein two of Y1, Y2 , Y3, Y4 and Y5 are present on adjacent carbon atoms and together constitute a methylenedioxy group;
where R independently may be -H; -F; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl, straight chained or branched C2-C7 alkenyl or alkynyl; -N(R3)2; -NO2; -CN; -CO2R3; -(CH2)pPO(OR3)2; -(CH2)pPO(OR3)3; or -OR3; where R1 may be -H; -NO2; -CN; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R3)2; -OR3; -(CH2)pOR3; -COR3; -CO2R3; or -CON(R3)2, wherein any p independently is an integer from 1 to 7 inclusive; where R2 may be -H; straight chained or branched C1-C7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2 -C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C3-C10 cycloalkyl -C1-C10-alkyl, C3-C-10cycloalkyl-C1-C10-monofluoroalkyl or C3-C10 cycloalkyl-C1-C10-polyfluoroalkyl; -CN; -CH2XR3, -CH2X(CH2)pNHR3, -(CH2)nNHR3, -CH2X(CH2)pN(R3)2, -CH2X(CH2)pN3, or -CH2X(CH2)pNHCXR7; or -OR3; wherein any n independently is an integer from 0 to 5 inclusive and p is as defined above; where each R3 independently may be -H; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C6 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -(CH2)pPO(OR8)2; -(CH2)pPO(OR8)3; or -(CH2)pCOOR8; where R4 has the structure
Figure imgf000085_0001
wherein Z may be C2-C7 alkenyl or alkynyl; CH2; O; CO; CO2; CONR3CO; CONR3; S; SO; SO2; or NR3; m is an integer from 0 to 3 inclusive;
R5 and R6 each independently may be -H; -F, -Cl, -Br, -I;
-CO2R3; -COR 3; -CON(R3)2; -CN; -NO, -N(R3)2; -OR3; straight chained or branched C1-C7 alkyl, Cl- C7 monofluoroalkyl, C1-C7 polyfluoroalkyl, C2-C7 alkenyl, C2-C7 alkynyl, C3-C7 cycloalkyl, or C3-C7 cycloalkenyl, wherein the alkyl, monofluoroalkyl, polyfluoroalkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl may be unsubstituted or substituted with -H, aryl or heteroaryl; aryl or heteroaryl wherein the aryl or heteroaryl may be unsubstituted or substituted with -H, -F,
-Cl, -Br, -I, -NO2, -CN, -N(R3)2, -OR3, -COR3 -CO2R3, or -CON(R3)2; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl, straight chained or branched C2-C7 alkenyl or alkynyl, C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl, or cycloalkenyl;
R7 may be -H; straight chained or branched C1-C7 alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monof luorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -CN; -CO2R3; -COR3; -CON(R3)2; or -OR3;
where R8 is -H; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; where R9 may be -H; -CN; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R3)2; -OR3; -(CH2)pOR3; -COR3; -CO2R3; or -CON(R3)2; wherein X may be S; O; or NR3; and wherein B may be -H; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, alkoxy or thioalkyl; straight chained or branched C2-C7 alkenyl; -SCH2C6H4OR3; -(CH2)nC6H5; -CH2X(CH2)nNHR3; -(CH2)nNHR3; or -OR3; or a pharmaceutically acceptable salt thereof.
The compound of claim 1, wherein the compound comprises the (+) enantiomer.
The compound of claim 1, wherein the compound comprises the (-) enantiomer. The compound of claim 1, wherein the compound is selected from the group consisting of:
Figure imgf000087_0001
Figure imgf000087_0002
and
Figure imgf000088_0001
The compound of claim 4, wherein R4 is
Figure imgf000088_0002
and p is 2, 3 or 4
6. The compound of claim 5, wherein R4 is
Figure imgf000089_0001
The compound of claim 6, having the structure
Figure imgf000089_0002
8. The compound of claim 7, wherein M is polyfluorophenyl and R5 is substituted or unsubstituted phenyl or pyridyl.
9. The compound of claim 8, wherein R1 is -CO2CH3, -COCH3, or -CONH2; R2 is -CH2OCH3, methyl or ethyl; and R6 is H, -CN, or CO2CH3.
10. The compound of claim 6, wherein the compound is selected from the group consisting of:
Figure imgf000090_0001
Figure imgf000090_0002
Figure imgf000091_0002
Figure imgf000091_0001
Figure imgf000092_0003
Figure imgf000092_0002
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000093_0002
and
Figure imgf000093_0003
The compound of claim 10, wherein the compound is the (+) enantiomer.
12. The compound of claim 10, wherein the compound is
the (-) enantiomer.
13. The compound of claim 6, having the structure
Figure imgf000094_0001
14. The compound of claim 13, wherein M is polyfluorophenyl and R5 is substituted or unsubstituted phenyl or pyridyl.
15. The compound of claim 14, wherein the compound is
Figure imgf000094_0002
16. The compound of claim 15, wherein the compound is the (+) enantiomer.
17. The compound of claim 15, wherein the compound is the (-) enantiomer.
18. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
19. The pharmaceutical composition of claim 18, wherein the amount of the compound is an amount from about 0.01 mg to about 500 mg .
20. The pharmaceutical composition of claim 19, wherein the amount of the compound is from about 0.1 mg to about 60 mg.
21. The pharmaceutical composition of claim 20, wherein the amount of the compound is from about 1 mg to about 20 mg.
22. The pharmaceutical composition of claim 18, wherein the carrier is a liquid and the composition is a solution.
23. The pharmaceutical composition of claim 18, wherein the carrier is a solid and the composition is a tablet.
24. The pharmaceutical composition of claim 18, wherein the carrier is a gel and the composition is a suppository.
25. The pharmaceutical composition of claim 18, wherein the compound is formulated as a part of a pharmaceutically acceptable transdermal patch.
26. A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 1 effective to treat benign prostatic hyperplasia.
27. A method of claim 26, wherein the compound additionally does not cause a fall in blood pressure at dosages effective to alleviate benign prostatic hyperplasia.
28. The method of claim 27, wherein the compound effects treatment of benign prostatic hyperplasia by relaxing lower urinary tract tissue.
29. The method of claim 28, wherein the lower urinary tract tissue is prostatic smooth muscle.
30. A method of treating a subject suffering from elevated intraocular pressure which comprises administering to the subject an amount of the compound of claim 1 effective to lower intraocular pressure.
31. A method of treating a subject suffering from a disorder associated with elevated blood cholesterol which comprises administering to the subject an amount of the compound of claim 1 effective to inhibit cholesterol synthesis.
32. A method of treating a disease which is susceptible to treatment by antagonism of the αlA receptor which comprises administering to the subject an amount of the compound of claim 1 effective to treat the disease.
33. A method of treating a subject suffering from impotency which comprises administering to the subject an amount of the compound of claim 1 effective to treat impotency.
34. A method of treating a subject suffering from sympathetically mediated pain which comprises administering to the subject an amount of the compound of claim 1 effective to treat sympathetically mediated pain.
35. A method of treating a subject suffering from cardiac arrhythmia which comprises administering to the subject an amount of the compound of claim 1 effective to treat cardiac arrhythmia.
36. A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject the compound of claim 1 in combination with a 5 alpha-reductase inhibitor in an amount effective to treat benign prostatic hyperplasia.
37. The method of claim 36, wherein the 5-alpha reductase inhibitor is finasteride.
38. A pharmaceutical composition comprising a therapeutically effective amount of a combination of the compound of claim 1 and finasteride and a pharmaceutically acceptable carrier.
39. The pharmaceutical composition of claim 38, comprising from about 0.01 mg to about 500 mg of the compound and about 5 mg finasteride.
40. The pharmaceutical composition of claim 38, comprising from about 0.1 mg to about 60 mg of the compound and about 5 mg finasteride.
41. The pharmaceutical composition of claim 38, comprising from about 1 mg to about 20 mg of the compound and about 5 mg finasteride.
42. A method of relaxing lower urinary tract tissue which comprises contacting lower urinary tract tissue with an amount of the compound of claim 1 effective to relax lower urinary tract tissue.
43. The method of claim 42, wherein the lower urinary tract tissue is prostatic smooth muscle.
44. The method of claim 43, wherein the compound additionally does not cause a fall in blood pressure.
45. A method of relaxing lower urinary tract tissue in a subject, which comprises administering to the subject an amount of the compound of claim 1 effective to relax lower urinary tract tissue.
46. The method of claim 45, wherein the lower urinary tract tissue is prostatic smooth muscle.
47. The method of claim 46, wherein the compound additionally does not cause a fall in blood pressure.
48. A method of inhibiting contraction of prostatic tissue, which comprises administering to the subject an amount of the compound of claim 1 effective to inhibit contraction of prostatic tissue.
49. The method of claim 48, wherein the prostatic tissue is prostatic smooth muscle.
50. The method of claim 49, wherein the compound additionally does not cause a fall in blood pressure.
51. The method of relaxing lower urinary tract tissue of claim 42, wherein the compound is administered in combination with finasteride.
PCT/US1996/018573 1995-11-16 1996-11-15 Dihydropyrimidines and uses thereof WO1997017969A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU10558/97A AU714287B2 (en) 1995-11-16 1996-11-15 Dihydropyrimidines and uses thereof
JP9519157A JP2000500470A (en) 1995-11-16 1996-11-15 Dihydropyrimidine and uses thereof
US09/068,782 US6228861B1 (en) 1995-11-16 1996-11-15 Dihydropyrimidines and uses thereof
EP96941406A EP0866708A4 (en) 1995-11-16 1996-11-15 Dihydropyrimidines and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AMPCT/US95/15025 1995-11-16
PCT/US1995/015025 WO1996014846A1 (en) 1994-11-16 1995-11-16 Dihydropyrimidines and uses thereof
US64877096A 1996-05-16 1996-05-16
US08/648,770 1996-05-16

Publications (1)

Publication Number Publication Date
WO1997017969A1 true WO1997017969A1 (en) 1997-05-22

Family

ID=26789880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/018573 WO1997017969A1 (en) 1995-11-16 1996-11-15 Dihydropyrimidines and uses thereof

Country Status (1)

Country Link
WO (1) WO1997017969A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
EP0988295A1 (en) * 1997-06-18 2000-03-29 Synaptic Pharmaceutical Corporation Heterocyclic substituted piperidines and uses thereof
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
EP1014973A1 (en) * 1997-06-18 2000-07-05 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
WO2000078730A1 (en) * 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
US6172066B1 (en) * 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6232318B1 (en) 1998-11-12 2001-05-15 Merck & Co., Ltd. Pyrimidinedione derivatives useful as alpha 1A adrenoceptor antagonists
US6235759B1 (en) 1998-10-29 2001-05-22 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists
US6316437B1 (en) 1999-09-30 2001-11-13 Merck & Co., Inc. Spirohydantoin compounds and uses thereof
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6326372B1 (en) 1999-09-30 2001-12-04 Merck & Co., Inc. Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
US6329393B1 (en) 1998-12-17 2001-12-11 Merck & Co., Inc. Crystalline pharmaceutically acceptable salts of an oxazolidinone derivative
US6339090B1 (en) 1998-07-30 2002-01-15 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
US6387893B1 (en) 1999-09-30 2002-05-14 Merck & Co., Inc. Spirotricyclic substituted azacycloalkane derivatives and uses thereof
US6436962B1 (en) 1999-09-30 2002-08-20 Merck & Co., Inc. Arylhydantoin derivatives and uses thereof
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EP1734963A2 (en) * 2004-04-02 2006-12-27 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
US7157461B2 (en) 2003-07-23 2007-01-02 Bristol-Myers Squibb Co. Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
US8835449B2 (en) 2011-11-11 2014-09-16 Pfizer Inc. 2-thiopyrimidinones
US9771332B2 (en) 2015-05-05 2017-09-26 Pfizer Inc. 2-thiopyrimidinones
US9908908B2 (en) 2012-08-30 2018-03-06 Jiangsu Hansoh Pharmaceutical Co., Ltd. Tenofovir prodrug and pharmaceutical uses thereof
RU2712210C1 (en) * 2019-07-10 2020-01-27 Общество с ограниченной ответственностью "Технофарм" Medicament for acceptance stimulating of the mesh implant after plastic repair of the ventral hernias

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5659778A (en) * 1979-10-23 1981-05-23 Showa Denko Kk Dimethylthienopyrimidione derivative
US4703120A (en) * 1986-04-28 1987-10-27 Ortho Pharmaceutical Corporation Furo(3,4-d)pyrimidine-2,4-dione derivatives and intermediates thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5659778A (en) * 1979-10-23 1981-05-23 Showa Denko Kk Dimethylthienopyrimidione derivative
US4703120A (en) * 1986-04-28 1987-10-27 Ortho Pharmaceutical Corporation Furo(3,4-d)pyrimidine-2,4-dione derivatives and intermediates thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0866708A4 *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172066B1 (en) * 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6255315B1 (en) 1997-06-18 2001-07-03 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
EP0988295A1 (en) * 1997-06-18 2000-03-29 Synaptic Pharmaceutical Corporation Heterocyclic substituted piperidines and uses thereof
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
EP1014973A1 (en) * 1997-06-18 2000-07-05 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
EP1014973A4 (en) * 1997-06-18 2000-09-20 Merck & Co Inc ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
EP0988295A4 (en) * 1997-06-18 2003-08-13 Synaptic Pharma Corp Heterocyclic substituted piperidines and uses thereof
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6339090B1 (en) 1998-07-30 2002-01-15 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
US6235759B1 (en) 1998-10-29 2001-05-22 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6232318B1 (en) 1998-11-12 2001-05-15 Merck & Co., Ltd. Pyrimidinedione derivatives useful as alpha 1A adrenoceptor antagonists
US6329393B1 (en) 1998-12-17 2001-12-11 Merck & Co., Inc. Crystalline pharmaceutically acceptable salts of an oxazolidinone derivative
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
US6855716B2 (en) 1999-06-23 2005-02-15 Ajinomoto Co., Inc. Dihydropyrimidine compounds and compositions containing the same
WO2000078730A1 (en) * 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
US6326372B1 (en) 1999-09-30 2001-12-04 Merck & Co., Inc. Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
US6387893B1 (en) 1999-09-30 2002-05-14 Merck & Co., Inc. Spirotricyclic substituted azacycloalkane derivatives and uses thereof
US6436962B1 (en) 1999-09-30 2002-08-20 Merck & Co., Inc. Arylhydantoin derivatives and uses thereof
US6316437B1 (en) 1999-09-30 2001-11-13 Merck & Co., Inc. Spirohydantoin compounds and uses thereof
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US7157461B2 (en) 2003-07-23 2007-01-02 Bristol-Myers Squibb Co. Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
EP1734963A2 (en) * 2004-04-02 2006-12-27 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
EP1734963A4 (en) * 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
EP2305352A1 (en) * 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US8835449B2 (en) 2011-11-11 2014-09-16 Pfizer Inc. 2-thiopyrimidinones
US8841314B2 (en) 2011-11-11 2014-09-23 Pfizer Inc. 2-Thiopyrimidinones
US9399626B2 (en) 2011-11-11 2016-07-26 Pfizer Inc. 2-thiopyrimidinones
US9873673B2 (en) 2011-11-11 2018-01-23 Pfizer Inc. 2-thiopyrimidinones
US9908908B2 (en) 2012-08-30 2018-03-06 Jiangsu Hansoh Pharmaceutical Co., Ltd. Tenofovir prodrug and pharmaceutical uses thereof
US9771332B2 (en) 2015-05-05 2017-09-26 Pfizer Inc. 2-thiopyrimidinones
RU2712210C1 (en) * 2019-07-10 2020-01-27 Общество с ограниченной ответственностью "Технофарм" Medicament for acceptance stimulating of the mesh implant after plastic repair of the ventral hernias

Similar Documents

Publication Publication Date Title
WO1997017969A1 (en) Dihydropyrimidines and uses thereof
US5942517A (en) 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6245773B1 (en) 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
WO1997042956A1 (en) Didhydropyrimidines and uses thereof
US8431580B2 (en) 4-aminopyrimidine derivatives as histamine H4 receptor antagonists
WO2009077608A1 (en) 2 -aminopyrimidine derivatives as histamine h4 antagonists
US6228861B1 (en) Dihydropyrimidines and uses thereof
US6268369B1 (en) 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6172066B1 (en) Dihydropyrimidines and uses thereof
US6046331A (en) Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
JP2002520408A (en) Compounds specific for human α1d adrenergic receptor and uses thereof
US6274585B1 (en) Dihydropyrimidines and uses thereof
EP0866708A1 (en) Dihydropyrimidines and uses thereof
US6680323B2 (en) Dihydropyrimidines and uses thereof
WO2000037026A1 (en) Dihydropyrimidines and uses thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 836628

Date of ref document: 19970516

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RU SD SE SG SI SK TJ TM TR TT UA UG US US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2237774

Country of ref document: CA

Ref country code: CA

Ref document number: 2237774

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 519157

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996941406

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996941406

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09068782

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1996941406

Country of ref document: EP